NZ617706B2 - Compositions and methods for improving the quality of processed sperm - Google Patents
Compositions and methods for improving the quality of processed sperm Download PDFInfo
- Publication number
- NZ617706B2 NZ617706B2 NZ617706A NZ61770612A NZ617706B2 NZ 617706 B2 NZ617706 B2 NZ 617706B2 NZ 617706 A NZ617706 A NZ 617706A NZ 61770612 A NZ61770612 A NZ 61770612A NZ 617706 B2 NZ617706 B2 NZ 617706B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- media
- osrs
- sperm cell
- sperm
- vitamin
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 146
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 48
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 48
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 48
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 48
- 238000010186 staining Methods 0.000 claims abstract description 29
- 235000020954 vitamin B12 vitamer Nutrition 0.000 claims abstract description 11
- 239000011620 vitamin B12 vitamer Substances 0.000 claims abstract description 11
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 5
- 238000007710 freezing Methods 0.000 claims description 31
- 230000008014 freezing Effects 0.000 claims description 31
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 claims description 22
- 210000001161 mammalian embryo Anatomy 0.000 claims description 22
- 235000013601 eggs Nutrition 0.000 claims description 17
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 15
- 239000002577 cryoprotective agent Substances 0.000 claims description 15
- 238000010257 thawing Methods 0.000 claims description 12
- 241000283690 Bos taurus Species 0.000 claims description 10
- 241000283153 Cetacea Species 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 241000282994 Cervidae Species 0.000 claims description 6
- 229930003427 Vitamin E Natural products 0.000 claims description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 6
- 235000019165 vitamin E Nutrition 0.000 claims description 6
- 239000011709 vitamin E Substances 0.000 claims description 6
- 229940046009 vitamin E Drugs 0.000 claims description 6
- 241000282979 Alces alces Species 0.000 claims description 4
- 241000282465 Canis Species 0.000 claims description 4
- 241000283073 Equus caballus Species 0.000 claims description 4
- 241000282324 Felis Species 0.000 claims description 4
- 241000282575 Gorilla Species 0.000 claims description 4
- 241000282898 Sus scrofa Species 0.000 claims description 4
- 239000011732 tocopherol Substances 0.000 claims description 4
- 229930003799 tocopherol Natural products 0.000 claims description 4
- 239000011731 tocotrienol Substances 0.000 claims description 4
- 229930003802 tocotrienol Natural products 0.000 claims description 4
- 235000019148 tocotrienols Nutrition 0.000 claims description 4
- 239000011550 stock solution Substances 0.000 claims description 3
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims 3
- 241001481833 Coryphaena hippurus Species 0.000 claims 3
- 241000282577 Pan troglodytes Species 0.000 claims 3
- 229960001295 tocopherol Drugs 0.000 claims 3
- 235000010384 tocopherol Nutrition 0.000 claims 3
- 239000011614 vitamin E vitamer Substances 0.000 claims 3
- 235000020962 vitamin E vitamer Nutrition 0.000 claims 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 3
- 210000004027 cell Anatomy 0.000 description 196
- 244000309464 bull Species 0.000 description 96
- 239000000523 sample Substances 0.000 description 90
- 230000004899 motility Effects 0.000 description 47
- 210000000582 semen Anatomy 0.000 description 36
- 238000012545 processing Methods 0.000 description 30
- 239000003963 antioxidant agent Substances 0.000 description 27
- 235000006708 antioxidants Nutrition 0.000 description 27
- 210000002257 embryonic structure Anatomy 0.000 description 21
- 239000010902 straw Substances 0.000 description 21
- 239000004606 Fillers/Extenders Substances 0.000 description 19
- 230000003078 antioxidant effect Effects 0.000 description 19
- 230000008569 process Effects 0.000 description 19
- 239000012530 fluid Substances 0.000 description 17
- 210000000287 oocyte Anatomy 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 210000002459 blastocyst Anatomy 0.000 description 13
- 238000005138 cryopreservation Methods 0.000 description 13
- 230000009027 insemination Effects 0.000 description 13
- 230000035882 stress Effects 0.000 description 13
- 230000035899 viability Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 230000035558 fertility Effects 0.000 description 12
- 230000004720 fertilization Effects 0.000 description 12
- 239000008188 pellet Substances 0.000 description 12
- 230000000750 progressive effect Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 238000012546 transfer Methods 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 10
- 229930003231 vitamin Natural products 0.000 description 10
- 235000013343 vitamin Nutrition 0.000 description 10
- 239000011782 vitamin Substances 0.000 description 10
- 229940088594 vitamin Drugs 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000012091 fetal bovine serum Substances 0.000 description 9
- 230000035800 maturation Effects 0.000 description 9
- 230000019100 sperm motility Effects 0.000 description 9
- 210000002593 Y chromosome Anatomy 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 230000035935 pregnancy Effects 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000013467 fragmentation Methods 0.000 description 6
- 238000006062 fragmentation reaction Methods 0.000 description 6
- 238000010791 quenching Methods 0.000 description 6
- 230000000171 quenching effect Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 5
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 230000012447 hatching Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 4
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 4
- 210000001766 X chromosome Anatomy 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000003501 co-culture Methods 0.000 description 4
- 210000001771 cumulus cell Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 4
- 229940028334 follicle stimulating hormone Drugs 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229940076788 pyruvate Drugs 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 235000020942 vitamer Nutrition 0.000 description 4
- 239000011608 vitamer Substances 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 229940015047 chorionic gonadotropin Drugs 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 210000002969 egg yolk Anatomy 0.000 description 3
- 235000013345 egg yolk Nutrition 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229960004821 amikacin Drugs 0.000 description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940034629 chorulon Drugs 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 230000006353 environmental stress Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000004017 vitrification Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- UPLPHRJJTCUQAY-WIRWPRASSA-N 2,3-thioepoxy madol Chemical compound C([C@@H]1CC2)[C@@H]3S[C@@H]3C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 UPLPHRJJTCUQAY-WIRWPRASSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000157855 Cinchona Species 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241001125840 Coryphaenidae Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 description 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- 239000007994 TES buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- FXKSEJFHKVNEFI-GCZBSULCSA-N amikacin disulfate Chemical compound [H+].[H+].[H+].[H+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O FXKSEJFHKVNEFI-GCZBSULCSA-N 0.000 description 1
- -1 and pseudo-B12) Chemical compound 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000013313 blastocyst growth Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009028 cell transition Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 235000006279 cobamamide Nutrition 0.000 description 1
- 239000011789 cobamamide Substances 0.000 description 1
- ZIHHMGTYZOSFRC-UWWAPWIJSA-M cobamamide Chemical compound C1(/[C@](C)(CCC(=O)NC[C@H](C)OP(O)(=O)OC2[C@H]([C@H](O[C@@H]2CO)N2C3=CC(C)=C(C)C=C3N=C2)O)[C@@H](CC(N)=O)[C@]2(N1[Co+]C[C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C3=NC=NC(N)=C3N=C1)O)[H])=C(C)\C([C@H](C/1(C)C)CCC(N)=O)=N\C\1=C/C([C@H]([C@@]\1(CC(N)=O)C)CCC(N)=O)=N/C/1=C(C)\C1=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]1CCC(N)=O ZIHHMGTYZOSFRC-UWWAPWIJSA-M 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 150000002211 flavins Chemical class 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 244000309465 heifer Species 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 235000004867 hydroxocobalamin Nutrition 0.000 description 1
- 239000011704 hydroxocobalamin Substances 0.000 description 1
- 229960001103 hydroxocobalamin Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008723 osmotic stress Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001706 oxygenating effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 125000003410 quininyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000009394 selective breeding Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 210000005089 vacuolized cytoplasm Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0278—Physical preservation processes
- A01N1/0284—Temperature processes, i.e. using a designated change in temperature over time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/04—Coculture with; Conditioned medium produced by germ cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0609—Oocytes, oogonia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/061—Sperm cells, spermatogonia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0612—Germ cells sorting of gametes, e.g. according to sex or motility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
-
- G01N2015/149—
Abstract
Disclosed is a method of sorting a sperm cell sample comprising the steps of: a. staining a sperm cell sample with a first media; and b. sorting the sperm cell sample to form at least one subpopulation in a second media; wherein at least one of the first media or the second media comprises two or more Organic Stress Reducing Agents (“OSRs”), and wherein one of the two or more OSRs is selected from the group consisting of vitamin B12, a vitamin B12 vitamer and biologically active derivatives thereof, each at a concentration in the range of 0.01 mg/ml to 5 mg/ml. Also disclosed is a gender sorted sperm cell composition comprising a gender sorted sperm cell sample and two or more OSRs each at a concentration in the range of 0.01 mg/ml to 5 mg/ml, wherein one of the two or more OSRs is selected from the group consisting of vitamin B12, a vitamin B12 vitamer and biologically active derivatives thereof. s two or more Organic Stress Reducing Agents (“OSRs”), and wherein one of the two or more OSRs is selected from the group consisting of vitamin B12, a vitamin B12 vitamer and biologically active derivatives thereof, each at a concentration in the range of 0.01 mg/ml to 5 mg/ml. Also disclosed is a gender sorted sperm cell composition comprising a gender sorted sperm cell sample and two or more OSRs each at a concentration in the range of 0.01 mg/ml to 5 mg/ml, wherein one of the two or more OSRs is selected from the group consisting of vitamin B12, a vitamin B12 vitamer and biologically active derivatives thereof.
Description
COMPOSITIONS AND METHODS FOR IMPROVING THE
QUALITY OF PROCESSED SPERM
This application claims priority to U.S. Provisional Applications 61/492,151 filed June 1,
2011, entitled “Method of sorting sperm cells into one or more subpopulations and methods of
treating sperm cells to improve motility;” 61/569,143 filed December 9, 2011, entitled “Methods
of handling processed sperm cells to improve their quality;” and 61/570,691 filed December 14,
2011, entitled “Methods of handling processed sperm cells to improve their quality,” the contents
of which are all incorporated by reference in their entireties.
The present invention generally relates to compositions and methods for the handling of
processed sperm populations, including those freshly collected as well as those sorted into one or
more subpopulations, and for treating processed and/or handled semen samples and solutions
that contain sperm cells to increase the overall quality of the processed sperm, including their
viability, motility, fertility, DNA integrity, and in vitro longevity. The present invention also
relates to compositions comprising sperm cells and at least one compound that may be an
antioxidant, vitamin or other organic stress reducer, the methods of using these compounds to
reduce trauma and stress on processed sperm, the resulting sperm and embryo end products, and
the methods of use of these products in assisted reproductive technologies (ART) to increase the
quality, quantity and viability of embryos, and improved rates of births in animals.
BACKGROUND
Assisted reproductive technology (ART) includes such techniques as in vitro fertilization
(IVF), artificial insemination (AI), intracytoplasmic sperm injection (ICSI) (other techniques
using enucleated cells) and multiple ovulation and embryo transfer (MOET) (as well as other
embryo transfer techniques), is used across the animal kingdom, including humans and other
animals. ART methods are usually expensive, time consuming and marginally successful given
the inherent fragility of gametes and embryos when outside of their natural environments.
Furthermore, the use of ART within the animal breeding industry in a commercially feasible
manner is additionally challenging due to the limited availability of genetically desirable gametes
and zygotes. One way to lower the cost of ART and to improve its commercial feasibility is to
increase the efficiency of the involved processes by improving the viability and overall quality of
gametes and zygotes. Although there is has been a growing interest in this field over the course
of the last decade or so, there still remains a strong need to increase the overall quality of
gametes and zygotes for use in ART, especially when breeding focuses on pre-natal gender
selection, including improving their viability (in the case of gametes and zygotes), their motility
and fertility (in the case of sperm cells), as well as other longevity characteristics.
For example, in conventional AI, one problem limiting its commercial application in
certain species is the need to use extremely high number of sperm cells per AI dose to ensure
successful fertilization. Similarly, in IVF, the percentage of zygotes that develop into embryos
remains frustratingly low; this high rate of loss significantly increases the cost of embryos and
related services to end-users. There also remains the need for more efficient and lower cost
procedures for improving post-embryo handling through cryopreservation as well as non-frozen
transport. Cryopreservation of embryos is limited by the success rate of embryo production as
well as blastocyst growth in vitro. Currently, only a marginal percentage of IVF embryos are
suitable for cryopreservation which adds to the ongoing high cost of ART procedures.
Especially when processing gametes such as flushed oocytes or sperm cells, both
conventional and sex-sorted, before their use in ART adds a tremendous amount of stress on the
gamete cell and negatively impacts their cellular integrity and membrane structure which in turn
is reflected in decreased viability, motility and fertility. An example of processing gametes prior
to their use in ART is the sorting of sperm cells based on sex (known as “gender enrichment” or
“sex-sorting”), which is a highly desired procedure to minimize wasted births of the wrong sex
for selective breeding in the livestock industry but is often cost prohibitive and can be risky to
those with smaller breeding herds.
The popular flow cytometry based sex-sorting process severely stresses and damages the
cells and produces a low percentage of useful sperm, which although capable of fertilizing
matured oocytes, have reduced viablity, motility and fertility after the sex-sorting process.
Typically, sex-sorting involves many harsh steps including but not limited to: the initial
collection and handling of sperm ejaculate which naturally starts to deteriorate rapidly upon
collection; the staining of sperm cells which involves binding of an excitable dye to the DNA or
a harmful membrane selection procedure; the physical sorting of the sperm cells using high
energy fluorescence that physically energizes the dye that is bound to the DNA, forced
orientation through a narrow orifice, and application of an electrical charge to the cell; the
physical collection of the cells into a container which often shocks the fragile cell upon contact;
the osmotic stresses associated with dilution of the sperm droplet in collection media; and the
storage of the sorted sperm usually by freezing which is well known to raise havoc with the
cell’s membrane systems. Each step places the processed sperm under abnormal stress which
diminishes the overall motility, viability and/or fertility of the sperm. The result can lead to less
efficient samples for use in ART, such as IVF and AI, and other types of subsequent or further
processing.
Even non-sorted processed sperm exhibits significant losses in fertility, viability and
motility when being collected, handled and transported without freezing, and noticeably
experiences significant stress when mixed with cryoprotectant and is frozen and thawed. Many
in the field have tried to improve methods for the use on unsorted, conventional semen to
minimize loss in the handling processes associated with in vitro handling, preservation and use
of semen samples.
Regardless of the processing, sperm lose their potential to fertilize when exposed to:
elevated temperatures, abnormal buffers, stains, altered pH systems, physical pressurized
orientation as when forced through a nozzle or when oscillated to form drops in a flow
cytometer, radiation used to illuminate the DNA binding dye, physical stressors associated with
separation and collection techniques, cryoprotectants, freezing, thawing and micromanipulation
by the handler.
The large class of compounds referred to as antioxidants have been associated with
providing beneficial effects to all sorts of cells, in vivo and in vitro, but these effects are as
varied as the nature of the antioxidant itself. An antioxidant is simply one of a large variety of
molecules that either inhibit the oxidation of another molecule, becomes oxidized itself in place
of the target substrate, or binds harmful free radical intermediates and interrupts oxidative chain
reactions within a cell. Most have dual roles; some are enzymes, others are non-enzymatic;
some others are vitamins and others are cofactors. Such diversity lauds the diversity of
antioxidants, but because of their known ability to minimize cell damage, they are frequently
lumped together as a single class of compounds having only a single function, to bind free
radicals.
Various antioxidants have shown promise in promoting cell integrity with some reports
showing positive effects on sperm motility and membrane integrity during cryopreservation, but
some tests have been shown to have minimal or even harmful effects on processed sperm.
Similarly, vitamins are again a rather diverse group of molecules having very different
biological properties. Vitamins are any of a large group of organic compounds required in very
small amounts as vital nutrients for an organism that cannot synthesize it. They can be
antioxidants, enzymes, hormones or non-enzymes; they can be regulators of cell growth, cell
differentiation or moderators of mineral metabolism.
To date, no studies have sufficiently addressed the use of antioxidants, vitamins or other
supplements in the routine handling of fragile gametes during in vitro processing, especially
during the harsh processing associated with the sex-sorting of sperm, whereby the end result is a
reproducible improvement on the viability, motility and fertility of extensively processed sperm
cells and embryos. There remains a continuing need to improve current methods of ART to
reduce the cost and to make the procedures more dependable and commercially feasible to those
on a tight budget, especially those smaller breeders who view sex-selection breeding as a high
risk and expensive option. It is an ojbect of the present invention to go someway towards
meeting this need and/or to provide the public with a useful choice.
SUMMARY OF THE INVENTION
The present invention is directed to improvements in the motility, viability, fertility and overall
integrity of processed sperm cells. Accordingly, in a first embodiment the present invention
provides a method of sorting a sperm cell sample comprising the steps of: a. staining a sperm cell
sample with a first media; and b. sorting the sperm cell sample to form at least one subpopulation
in a second media; wherein at least one of the first media or the second media comprises two or
more Organic Stress Reducing Agents (“OSRs”), and wherein one of the two or more OSRs is
selected from the group consisting of vitamin B12, a vitamin B12 vitamer and biologically active
derivatives thereof, each at a concentration in the range of 0.01 mg/ml to 5 mg/ml.
In a second embodiment, the present invention provides a sperm sample sorted by the
method of the invention.
In a third embodiment, the present invention provides a method of fertilizing one or more
non-human eggs comprising the steps of:
a. adding a first media to a sperm cell sample;
b. staining the sperm cell sample in the first media;
c. sorting the sperm cell sample to form one or more subpopulations of sperm cells;
d. collecting the subpopulation of sperm cells in a second media;
e. mixing the subpopulation of sperm cells with one or more non-human eggs to
fertilize one or more of the eggs;
wherein the first media and/or the second media comprises two or more OSRs each at a
concentration in the range of 0.01 mg/ml to 5 mg/ml, wherein one of the two or more OSRs is
selected from the group consisting of vitamin B12, a vitamin B12 vitamer and biologically active
derivatives thereof, and wherein the first media or the second media comprising the two or more
OSRs may be prepared before addition to the sperm cell sample or by addition of a stock
solution comprising the two or more OSRs to the sperm cell sample.
In a fourth embodiment, the present invention provides a non-human, sorted embryo
produced by the method of the invention.
In a fifth embodiment, the present invention provides a gender sorted sperm cell
composition comprising a gender sorted sperm cell sample and two or more OSRs each at a
concentration in the range of 0.01 mg/ml to 5 mg/ml, wherein one of the two or more OSRs is
selected from the group consisting of vitamin B12, a vitamin B12 vitamer and biologically active
derivatives thereof.
Also described is a method of treating sperm cells by adding at least one “organic stress
reducing” agent (OSR) which may comprise an antioxidant, a vitamin or other organic molecule
involved directly or indirectly in modulating physiological stresses in the cell. The OSR would
be added in the concentration range of 0.01 mg/ml to 5 mg/ml to a sperm cell sample to form a
sperm cell composition. In certain embodiments, one or more OSRs, each in the concentration
range of 0.01 mg/ml to 5 mg/ml, can be added to the sperm cell sample prior to cryopreservation
(including, for example, freezing and vitrification), after the sperm cell sample has been thawed,
or at both times. In other embodiments, the OSR can be added at one or more of the various
stages during the sperm cell processing procedure. The term “sperm cell sample” may comprise
a processed semen sample or an unsorted, conventional semen sample.
Also described is a sperm cell composition comprising a sperm cell sample and at least
one OSR in the concentration range of 0.01 mg/ml to 5 mg/ml. Another embodiment
encompasses a “sperm cell composition” comprising a sperm cell sample, at least one OSR in the
concentration range of 0.01 mg/ml to 5 mg/ml and a cryoprotectant. Most cryoprotectants can be
used with the invention, including but not limited to egg yolk, propylene glycol, dimethyl
sulfoxide, sucrose, ethylene glycol and glycerol, or a combination thereof. One embodiment
encompasses a fresh, an unfrozen, a frozen, a vitrified, or a thawed sperm cell composition
comprising a sperm cell sample and at least one OSR in the concentration range of 0.01 mg/ml to
mg/ml. Another embodiment encompasses a fresh, an unfrozen, a frozen, a vitrified, or a
thawed sperm cell composition comprising a sperm cell sample, at least one antioxidant and/or
one vitamin in the concentration range of 0.01 mg/ml to 5 mg/ml, and a stain.
Another broad object of the present disclosure is to improve the motility, viability
(including longevity and ability to survive environmental stress) and/or fertility of sperm cells,
each contributing to the sperm cell’s overall integrity, to improve the success of using ART,
including techniques such as IVF, AI, ICSI (as well as other techniques using enucleated cells),
and MOET (as well as other embryo transfer techniques).
Such ART techniques involve different levels of gamete cell processing which in the case
of sperm can entail, by example only and is not limited to one or more of the following:
artificially collecting a semen sample from the male animal which may involve natural,
electronic or other types of sexual stimulation; holding; transporting; buffering with different
pHs; chilling; warming; staining; diluting; concentrating; energetically exciting as with a laser;
electronic charging; deflecting; ablating to kill unwanted cells usually with targeted lasers;
sorting; collecting; shaking; oscillating; magnetically separating; oxygenating as associated with
microchip sorting procedures; labeling; precipitating; centrifuging; resuspending; mixing;
dialyzing; cryostabilizing; freezing; vitrification; thawing; culturing; inseminating;
microinjecting; microfluidic processing; microchip processing; jet and air processing; flow
cytometry processing; and similar handling techniques. Whereas a single processing step may
exert only minimal stress on a sperm cell, others or a combination may add significant stress,
often killing the cell. An extreme example is the sex-sorting process used to separate X- from Y-
chromosome bearing cells; the sorting process combines a large number of independent highly
stressful steps that severely compromise the overall integrity of the sorted sperm cell population.
Accordingly, one embodiment of the present disclosure resides broadly in the use of a
sperm cell composition, comprising a sperm cell sample and at least one antioxidant and/or at
least one vitamin in the concentration range of 0.01 mg/ml to 5 mg/ml, in ART. One specific
embodiment comprises a method of increasing the percentage of zygotes that develop into
embryos in a given sample in a given amount of time, as well as increasing the percentage of
embryos that are suitable for cryopreservation (i.e., the percentage of embryos that are
blastocysts, expanded and hatching blastocysts, or hatched blastocysts), by mixing an egg with a
sperm cell sample that has been treated with at least one OSR in the concentration range of 0.01
mg/ml to 5 mg/ml. A further embodiment resides in a method of making an embryo comprising
mixing at least one egg with a sample of sperm cells treated with at least one OSR in the
concentration range of 0.01 mg/ml to 5 mg/ml. The embryos produced by this method constitute
a further embodiment described herein. Another embodiment includes a method for inseminating
an organism through an AI technique using a sperm cell sample treated with at least one OSR in
the concentration of 0.01 mg/ml to 5 mg/ml. Another embodiment includes a method of
transferring an embryo into a receptive female (ET) where said embryo is made using a sperm
cell sample treated with at least one OSR in the concentration of 0.01 mg/ml to 5 mg/ml. The
progeny of the organism that results from the aforementioned AI method also constitutes an
embodiment described herein.
Most embodiments described herein utilize concentrations of OSRs selected from the
following ranges: 0.01 to 5.0 mg/ml; 0.01 to 0.25 mg/ml; 0.01 to 0.5 mg/ml; 0.01 to 1 mg/ml;
0.01 to 2.5 mg/ml; 0.01 to 5 mg/ml; 0.05 to 0.1 mg/ml; 0.05 to 1.0 mg/ml; 0.05 to 2.5 mg/ml;
0.1 to 0.25 mg/ml; 0.1 to 0.5 mg/ml; 0.1 to 1 mg/ml; 0.1 to 2.5 mg/ml; 0.1 to 5 mg/ml; 0.15 to
0.45 mg/ml; 0.15 to 0.5 mg/ml; 0.25 to 0.35 mg/ml; 0.25 to 0.5 mg/ml; 0.25 to 1 mg/ml; 0.25 to
2.5 mg/ml; 0.25 to 5 mg/ml; 0.35 to 0.5 mg/ml; 0.35 to 1 mg/ml; 0.35 to 2.5 mg/ml; 0.35 to 5
mg/ml; 0.5 to 1 mg/ml; 0.5 to 2.5 mg/ml; 0.5 to 5 mg/ml; 1 to 2.5 mg/ml; 1 to 5 mg/ml; about
0.05 mg/ml; about 0.1 mg/ml; about 0.15 mg/ml; about 0.25 mg/ml; about 0.35 mg/ml; about
0.45 mg/ml; and about 0.5 mg/ml.
In some embodiments described herein the sperm cell composition can be used
immediately or processed within the first few minutes after addition of the OSR for whatever
processing step is needed, whereby the holding period would be in the range 2 sec to 3 min. In
other embodiments, the sperm cell composition is held after the addition of the OSR(s) to allow
the OSR(s) to incorporate into the cells and effectuate protective effects on the cell population.
Such holding periods can be short, as in the range of a 3-15 minutes, moderate as in the range of
min to 1 hr; and longer processing periods ranging up to about 8 hrs or overnight for
extensive processing such as with sex-sorting techniques. Transportation hold periods associated
with transporting unfrozen sperm cell compositions can be much longer, extending up to a few
days, which may for example occur if the sample is collected, treated with the addition of one or
more OSRs, transported or shipped to another location possibly by air, and further processed at
the second location as for sex-sorting at a designated facility. In other instances, the sperm cell
composition might need to be held for a few days while a recipient female is hormonally prepped
for artificial insemination, as might occur if a sample is mistakenly thawed and cannot be
refrozen. The addition of OSRs could theoretically prolong these extended hold periods over
what is currently accepted in the art, and could provide sufficient protection to the sperm in the
sperm cell composition so that they could remain viable and fertile for up to a week or more.
In some embodiments described herein, the OSR is added several times during a complex
processing procedure to minimize cell stress throughout the procedure. In other embodiments,
the OSR is added only at one or more particular steps which are notably harsh on the cells to
help minimize stress and fatigue on the sperm cells. By way of example, the staining process
during sex sorting is often performed at non-physiological pH and at elevated temperatures, both
known to be harsh on the cells. Similarly, cryopreservation is also extremely harsh on the cells
and disrupts cell membranes, both internal and external. Following an intensive multi-step
sorting procedure, sex-sorted sperm cells which are already compromised are even more
susceptible to cryogenic and freeze processing.
Various OSRs can be used in the context of the current disclosure, including but not
limited to: catalase, superoxide dismutase (SOD), SOD mimics, glutathione, glutathione
reductase, glutathione peroxidase, pyruvate, mercaptoethanol, butylated hydroxytoluene (BHT),
lipoic acid, flavins, quinines, vitamin K (and related vitamers), vitamin B12 (and related
vitamers), with ‘vitamers’ defined as compounds having the same vitamin activity (such as
cobalamin, cyanocobalamin, methylcobalamin, adenosylcobalamin, hydroxocobalamin, and
pseudo-B12), vitamin E (including its vitamers, tocopherols (α, β, γ), tocotrienols, and α-
tocopheryl), alpha-ketoglutarate (also known as α-KG, AKG or oxo-glutarate) and various
biological forms of AKG (such as arginine, aspartate, lysine, and similar derivatives), other
compounds that regulate nitric oxide in the cell including malondialdehyde (MDA) and
asymmetric dimethylarginine (ADMA) and biologically active derivatives thereof .
A further embodiment described herein comprises a method of sorting a sperm cell
sample to form one or more subpopulations comprising the steps of providing a sperm cell
sample, sorting the sperm cell sample to form one or more subpopulations and adding at least
one OSR to the sperm cell sample during one or more of the aforementioned sorting steps, the
concentration of the OSR being in the range of 0.01 mg/ml to 5 mg/ml.
An additional embodiment of the disclosure encompasses media used in processing
sperm cells that comprise at least one OSR at the appropriate stock concentration to be present at
a final processing concentration in the range of 0.01 mg/ml to 5 mg/ml in the sperm cell
composition at the time of processing. A stress reducing media can be used for different
processes including but not limited to sperm collection, artificial insemination, sperm sorting, in
vitro fertilization, embryo culture, as well as sperm and embryo freezing. Media used in the
sorting of sperm cells typically comprise one or more buffers and/or extenders (i.e., substances
that preserve the viability and/or fertility of sperm cells).
Any buffer or buffer solution used in the processing of sperm can be used in the
aforementioned media, including but not limited to phosphates, citrates, acetates, lactates, and
combinations thereof, or a solution containing a salt, a carbohydrate, or a combination thereof
can be employed in some of the embodiments disclosure, such as, but not limited to: Tris, TES,
HEPES, TALP, TCA, PBS, citrate, milk and derivatives thereof, as discussed in detail in U.S.
Patent 7,208,265 the contents of which is hereby incorporated by reference in its entirety.
Any extender used in the processing of sperm can be used in the aforementioned media,
including but not limited to energy sources, protein sources and antibiotics and may include one
or more of the following: mono- and disaccharides, such as fructose, glucose, mannose, sucrose,
and lactose; protein sources, such as egg yolk, milk, BSA and derivatives thereof; and any one of
the commonly known antimicrobial or antibiotic agents, such as gentamicin, lincomycin,
spectinomycin, their derivatives, or any combination thereof.
As used herein, the term “extender” may also include certain organic substances such as
disaccharides, trisaccharides, and any combination thereof, egg yolk, milk, albumin, lecithin,
cholesterol, their derivatives and any combination thereof. An extender may also include a
detergent that may be an alkyl ionic detergent, such as sodium dodecyl sulfate (SDS).
Also described is a method of improving the motility, viability and/or fertility of a sperm
cell sample that has already undergone a sorting process, including but not limited to sex sorting,
comprising the step of adding at least one OSR in the concentration range of 0.01 mg/ml to 5
mg/ml to a sorted sperm cell sample to form a sperm cell composition.
Accordingly, described is the use of a sperm cell composition, that in some embodiments
comprise a sorted sperm cell sample and at least one OSR in the range of 0.01 mg/ml to 5 mg/ml,
for use in ART. A further embodiment encompasses a sperm cell composition comprising sorted
sperm cells, at least one OSR in the concentration range of 0.01 mg/ml to 5 mg/ml and a catch
media (i.e., media found in the vessel that receives, or catches, the sorted sperm at the end of the
sorting process). Another embodiment encompasses a sperm cell composition comprising a
processed or sorted sperm cell sample, an OSR in the concentration range of 0.01 mg/ml to 5
mg/ml, and a cryoprotectant. An additional embodiment described herein encompasses a frozen
or vitrified sperm cell composition comprising a processed or sorted sperm cell sample, and at
least one OSR in the concentration range of 0.01 mg/ml to 5 mg/ml.
Another broad object of the present disclosure is to improve the motility, viability
(including longevity and ability to survive environmental stress) and fertility of processed and/or
sorted sperm cells for use in ART such as IVF, AI, ICSI (as well as other techniques using
enucleated cells), and MOET (as well as other embryo transfer techniques).
Accordingly, some of the embodiments described herein incorporate the use of sex sorted
sperm cells that have had an OSR in the concentration range of 0.01 mg/ml to 5 mg/ml added to
them in ART.
Accordingly, other embodiments described herein incorporate the use of a sperm cell
composition, a sorted sperm cell sample, and at least one OSR in the concentration range of 0.01
mg/ml to 5 mg/ml, in ART.
One specific embodiment described herein comprises a method of increasing the
percentage of zygotes that develop into embryos in a given sample in a given amount of time, as
well as increasing the percentage of embryos that are suitable for cryopreservation (i.e., the
percentage of embryos that are blastocysts, expanded and hatching blastocysts, and hatched
blastocysts), by mixing an egg with a sorted sperm cell sample that has been treated with at least
one OSR in the concentration range of 0.01 mg/ml to 5 mg/ml.
A further embodiment described herein resides in a method of making an embryo
comprising mixing at least one egg with at least one sperm cell treated with at least one OSR in
the concentration range of 0.01 mg/ml to 5 mg/ml. The embryos produced by this method
constitute a further embodiment of the invention.
Other embodiments described herein also include, a method for inseminating an organism
through an AI technique using a processed or sorted sperm cell sample treated with at least one
OSR in the concentration of 0.01 mg/ml to 5 mg/ml. The progeny of the organism that results
from the aforementioned AI method also constitutes an embodiment of the disclosure.
Furthermore, one embodiment described herein encompasses a method for recovering embryos
that are produced from the aforementioned AI method.
Embodiments described herein can include sperm cells, or spermatozoa, collected from
numerous species of male mammals, and the invention should be understood not to be limited to
the species of male mammals described by the specific examples within this application. Rather
the specific examples within this application are intended to be illustrative of the varied and
numerous species of male mammals from which semen can be collected and utilized in certain
embodiments described herein. Embodiments of the invention, for example, may include the
sperm cells of humans as well as animals having commercial value for meat or dairy production
such as swine, ovine, bovine, equine, deer, elk, buffalo, or the like (naturally the mammals used
for meat or dairy production may vary from culture to culture). It may also include the sperm
cells of various domesticated mammalian species encompassed by canines and felines, as well as
sperm cells of primates, including but not limited to chimpanzees, gorillas, or humans and the
spermatozoa from whales, dolphins and other marine mammals. It may also include frozen-
thawed sperm cells from all the various mammals above-described and further, including but not
limited to, the sperm cells of deceased donors, from rare or exotic mammals, zoological
specimens, or endangered species.
BRIEF DESCRIPTION OF THE DRAWINGS
In order that the invention may be more clearly understood, preferred embodiments of the
present disclosure will now be described by way of example only with reference to the
accompanying sheets of drawings wherein:
Figure 1 is a schematic representation of part of a flow cytometer illustrating a method of
sorting a sperm cell sample into one or more subpopulations according to some embodiments of
the present invention.
Figure 2 illustrates a graphical representation of the motility and progressive motility found
in Table 1.
Figure 3 is a graphical representation of the percent blastocysts and percent hatching found in
Table 4.
Figure 4 is a graphical representation of the percent blastocysts and percent hatching found in
Table 5.
Figure 5 is a graphical representation of the percent motile sperm found in Table 1.
Figure 6 is a graphical representation of the percent progressively motile sperm found in
Table 1.
DETAILED DESCRIPTION OF THE INVENTION
In one aspect described herein, Figure 1 illustrates in schematic form part of a flow
cytometer used in a method to sort a sperm cell sample to form one or more subpopulations, the
flow cytometer being generally referenced 10. In this particular embodiment sex sorting is taking
place so the subpopulations are X-chromosome bearing sperm cells and Y-chromosome bearing
sperm cells. Figure 1 represents a single technique for sorting semen, but any known technique
for sorting cells known in the art can be used with certain embodiments of the invention.
Additional details of the basic sperm sorting apparatus and methodology are described in U.S.
Patents 5,135,759 and 7,371,517, the contents of which are hereby incorporated by reference in
their entireties.
Once a sperm cell sample has been collected it can be extended as soon after collection
with an extender that includes one or more antioxidants or vitamins. The sample is then typically
held at a temperature of about 5°C for between about 12 hours to about 18 hours while it is being
shipped from the collection point to the flow cytometer 10 for the sorting process. This holding
temperature can be in the range of between 4°C and 39°C and is commonly in the range of 4°C
and 16°C.
Upon arrival at the flow cytometer, the sample is stained with a DNA selective dye and a
quenching dye to form a stained sperm cell sample and subsequently placed into a sperm cell
source 11 of the flow cytometer 10. The flow cytometer 10 can be programmed by an operator
to generate two charged droplet streams, one containing X-chromosome bearing sperm cells,
charged positively, 12, one containing Y-chromosome bearing sperm cells, charged negatively
13 while an uncharged undeflected stream of dead cells 14 simply goes to waste.
An operator may also choose to program the flow cytometer in such a manner, that both
the X- and Y-chromosome bearing sperm are collected using a “high purity sort” (in other words
only live X- and Y-chromosome bearing sperm are collected) or to program the flow cytometer
to collect both the X- and Y-chromosome bearing sperm using an “enriched sort” (in other words
it will collect droplets containing live that were not previously sorted and excluding all initial
dead again by the use of Boolean Gate logic available with the computer that controls the flow
cytometer). The Boolean Gate logic can also be used to collect only one of either the X- or Y-
chromosome bearing sperm.
Initially, a stream of sperm cells under pressure, is deposited into the nozzle 15 from the
sperm cell source 11 in a manner such that they are able to be coaxially surrounded by a sheath
fluid supplied to the nozzle 15 under pressure from a sheath fluid source 16. An oscillator 17
which may be present can be very precisely controlled via an oscillator control mechanism 18,
creating pressure waves within the nozzle 15 which are transmitted to the coaxially surrounded
sperm cell stream as it leaves the nozzle orifice 19. As a result, the exiting coaxially surrounded
sperm cell stream 20 could eventually and regularly form droplets 21.
The charging of the respective droplet streams is made possible by the cell sensing
system 22 which includes a laser 23 which illuminates the nozzle exiting stream 20, and the light
emission of the fluorescing stream is detected by a sensor 24. The information received by the
sensor 24 is fed to a sorter discrimination system 25 which very rapidly makes the decision as to
whether to charge a forming droplet and if so which charge to provide the forming drop and then
charges the droplet 21 accordingly.
A characteristic of X-chromosome bearing sperm is that they tend to absorb more
fluorochrome dye than Y-chromosome bearing sperm and as such, the amount of light emitted
by the laser excited absorbed dye in the X- chromosome bearing sperm differs from that of the
Y-chromo-some bearing sperm and this difference in characteristic tells the sorter discrimination
system 25 which charge to apply to droplets containing only X- or only Y- chromosome bearing
sperm cells. Dead cells (or those about to die) have absorbed the quenching dye and the sorter
discrimination system 25 does not charge droplets containing such cells.
The charged or uncharged droplet streams then pass between a pair of electrostatically
charged plates 26, which cause them to be deflected either one way or the other or not at all
depending on their charge into respective collection vessels 28 and 29 to form respectively a
gender enriched population of X-chromosome bearing and a gender enriched Y-chromosome
bearing sperm cells having a DNA selective dye associated with their DNA. The uncharged non-
deflected stream containing a sub-population of dead cells (or those that are about to die) go to
the waste container 30.
The collected sex sorted sperm cells may then be frozen and stored or frozen and sent on
for further processing (or simply used for further processing immediately), further processing
meaning for example, the purposes of research or for use in ART such as IVF, AI, ICSI (as well
as other techniques using enucleated cells), and MOET (as well as other embryo transfer
techniques).
In alternative embodiments not illustrated, the catch media contained in the otherwise
empty collection vessels may also contain OSR in the concentration range of 0.01mg/ml to
5mg/ml. The OSR may be added during this stage of the sorting process (be it sex sorting or
other form of sorting) and/or in addition to another method step in the sorting (be it sex sorting or
other form of sorting) process.
Furthermore, in the alternative embodiments, the OSR administered in the concentration
range of 0.01 mg/ml to 5 mg/ml to the sperm cell sample or composition can be added to the
DNA selective dye and/or the quenching dye solutions. Some embodiments include use of one or
more OSRs as pre-mixed components of the prepared buffers, extenders, stains, catch fluids,
and/or cryo-extenders used in the sex sorting procedure. Accordingly, the OSR may be added to
the sperm cell sample at one or more steps during sex-sorting, including when the sperm cell
sample is being first handled following collection, and/or stained with a DNA selective dye
and/or the quenching dye, and/or at the time of collection from the flow cytometer, and/or later
when preparing the sample for cryopreservation by adding the OSR or OSR cocktail to the cryo-
extender.
Likewise, some sorting embodiments include sorting of frozen-thawed conventional
semen whereby the OSR can be added to the thawed semen sample shortly after thawing and
then reverse sorted to produce sex-sorted sperm cell subpopulations which include the addition
of an OSR at one or more steps during the extended processing procedure of gender selection.
In some cases, when the sorting of sperm cells is not going to involve sex sorting, a
quenching dye without the need for a DNA staining dye may be required, in which case the OSR
will only be present in the quenching dye to form the stained sample. In this way, depending on
the embodiment chosen, the OSR may again only be added during this stage of the sorting
process (be it sex sorting or other form of sorting) or in addition to at least one other method step
in the sorting (be it sex sorting or other form of sorting) process.
Again, in the alternative embodiments, the collected sex sorted sperm cells (or in
alternative embodiments the sorted, i.e. non-sex sorted sperm cell samples) once frozen will,
prior to such further processing, require to be thawed. Either before freezing or upon thawing,
the antioxidant, again in the concentration range of 0.01mg/ml to 5mg/ml, may be added to the
sample before freezing and/or to the thawed sample. In this way, depending on the embodiment
chosen, the OSR may again only be added during this stage of the sorting process (be it sex
sorting or other form of sorting) or in addition to at least one other method step in the sorting (be
it sex sorting or other form of sorting) process.
In yet further alternative embodiments the time period allowed to elapse after the addition
of the OSR, can vary and may be in the range of about 5 seconds to about 72 hours (excluding
freezing time and time spent in the freezer or in the cryopreserved state), the lower end of the
scale providing for almost immediate sorting of the sperm sample while the upper end of the
scale would cover the typical maximum time frame associated with moving a sperm sample from
its collection point to its sorting point. This is usually a flight and/or road travel time. More
particularly, the time periods may be about 5 seconds to about 3 hours; about 3 hours to about 6
hours; about 6 hours to about 12 hours; about 12 hours to about 18 hours; about 18 hours to
about 24 hours; about 24 hours to about 36 hours; about 36 hours to about 48 hours; about 48
hours to about 60 hours; and about 60 hours to about 72 hours; and .
Another alternative embodiment may include the use of an extender within a pH range of
.5 to 7.8, and frequently at about 6.5; about 6.6; about 6.7; about 6.8; about 6.9; about 7.0;
about 7.1; about 7.2; about 7.3; about 7.4; or about 7.5.
As described in the illustrated embodiment, different steps of the method are carried out
at different temperatures. In alternative embodiments, at least one of the method steps is carried
out within a temperature range selected from the group consisting of about 5°C to about 15°C;
about 15°C to about 20°C; about 20°C to about 25°C; about 25°C to about 30°C; about 30°C to
about 35°C; about 35°C to about 40°C and about 40°C to about 45°C. This allows for different
steps in the sorting method to be performed within different temperature ranges.
Also described is a method of treating the motility of sperm cells in a sperm cell sample.
In this embodiment, the sperm cell sample, which may be a gender enriched population of X-
chromosome bearing or Y-chromosome bearing sperm cells having a DNA selective or DNA
binding dye associated with their DNA, a sample sorted into one or more subpopulations or a
conventional non-sorted sample, the method of treating the motility of the sperm cells in the
sperm cell sample comprises the step of adding an OSR in the concentration range of 0.01 mg/ml
to 5mg/ml to the sperm cell sample to form a sperm cell composition (and in this embodiment at
a concentration of 0.5 mg/ml). The OSR which is added forms part of an extender which is in a
pH range of 6.5 to 7.5 and in particular embodiments, the pH is selected from the group
consisting of about 6.5; about 6.6; about 6.7; about 6.8; about 6.9; about 7.0; about 7.1; about
7.2; about 7.3; about 7.4; and about 7.5.
After the addition of the antioxidant, a time period being in the range of about 5 seconds
to about 72 hours is allowed to elapse before the sample undergoes further processing in the form
of for example, research or for use in assisted reproductive technologies such as IVF, AI, ICSI
(as well as other techniques using enucleated cells), and MOET (as well as other embryo transfer
techniques). The time period which is allowed to elapse may be selected from the range
consisting of: about 5 seconds to about 3 hours; about 3 hours to about 6 hours; about 6 hours to
about 12 hours; about 12 hours to about 18 hours; about 18 hours to about 24 hours; about 24
hours to about 36 hours; about 36 hours to about 48 hours; about 48 hours to about 60 hours; and
about 60 hours to about 72 hours. The techniques for fertilizing an egg involve the added step of
mixing at least one egg with the sperm cell sample. Any conventional technique such as those
listed above can be used in the methods described herein, including any conventional IVF or AI
technique. Typical IVF techniques are disclosed in WO/0243486, for example, which is
incorporated by reference herein in its entirety. Typical AI techniques are disclosed in U.S.
Patent No. 6,149,867, for example, which is incorporated by reference herein in its entirety.
In alternative embodiments, the sperm cell sample may have been a frozen sample that
has been allowed to thaw. The method may further comprise the step of staining the sperm cell
sample or the sperm cell composition with a DNA selective dye if the sample is not a sex sorted
sample.
The method may also comprise the step of freezing the sperm cell composition to form a
frozen sperm cell composition that may be allowed to thaw. At least one of the method steps in
this second aspect described herein is carried out within a temperature range selected from the
group consisting of about 0°C to about 5°C; about 5°C to about 15°C; about 15°C to about 20°C;
about 20°C to about 25°C; about 25°C to about 30°C; about 30°C to about 35°C; about 35°C to
about 40°C and about 40°C to about 45°C. Thus, each method step may be carried out at a
different or similar temperature range.
SUGGESTED METHODS
By way of example, the following oocyte maturation procedure, IVF procedure, in vitro
culture procedure and co-culture procedure may be used with the methods described herein. One
skilled in the art will know that variations on these methods exist and that these methods should
not be construed to limit the functionality of the current disclosure. These methods are
illustrative only.
1. Oocyte Collection. Collect slaughterhouse oocytes, wash 1X with about 3mL Hepes
washing media and with 1X with TCM-199 (Invitrogen, Carlsbad, CA) + 10% Fetal Bovine
Serum (FBS). Culture in maturation media for 22 hrs in a CO incubator at 38.5°C. In one
embodiment, the maturation media contains TCM-199, FBS, pyruvate, chorionic gonadotropin
(e.g., Chorulon (Intervet, Summit NJ)), follicle stimulating hormone (FSH) (e.g., Folltropin
(Bioniche, Belleville, Canada)), estradiol, and at least one antibiotic. In a further embodiment,
Amikacin (Sigma-Aldrich, St. Louis, MO) can be used as the antibiotic. In another embodiment,
the maturation media may also comprise luteinizing hormone.
In one embodiment, the maturation media may comprise 5-20 ml of TCM-199 Earl’s;
0.5-2ml of FBS (Thermo Fisher Scientific, Waltham, MA); 10-30 µl of pyruvate (prepared by
adding 0.05-0.20 g of sodium pyruvate (Sigma-Aldrich, St. Louis, MO) to 5-20 ml of saline
solution); 50-200 µl of chorionic gonadotropin (prepared by adding 5-20 UI of Chorulon
(Intervet, Summit NJ) to 5-20 ml of TCM-199 Earl’s); 5-20 µl of FSH (prepared by adding
0.001-0.01 g of Folltropin (Bioniche, Belleville, Canada) to 5-20 ml of TCM-199 Earl’s); 5-20 µl
of estradiol (prepared by adding 0.001-0.05 g of estradiol (Sigma-Aldrich, St. Louis, MO) to 5-
ml of Etanol (Sigma-Aldrich, St. Louis, MO)); and 10-30 µl Amikacin (prepared by adding
0.1-1 g Amikacin sulfate salt (Sigma-Aldrich) to 20-40 ml of saline solution). In alternative
embodiments, the maturation media may comprise the aforementioned components using
different volumes but in the same proportion to each other, e.g., in one embodiment, the
maturation media may comprise 10-40 ml of TCM-199; 1-4 ml of FBS; 20-60 µl of sodium
pyruvate, etc. In a further embodiment, the maturation media comprises the above preparations
of TCM-199 Earl’s, FBS, pyruvate, chorionic gonadotropin, FSH, estradiol and an antibiotic in
the approximate ratio of 9 : 1 : 0.02 : 0.1 : 0.01: 0.01 : 0.02 by volume, respectively.
2. In Vitro Fertilization. Trim away cumulus cells from matured oocytes. Transfer them
to a fertilization dish and return to the CO incubator. Thaw frozen semen straws using standard
procedures, centrifuge in 800µL of Pure Sperm gradient (Nidacon, Molndal, Sweden), or a
percoll or similar gradient at 2500 RPM for 10 minutes to remove egg components, glycerol and
other debris. Remove supernatant, leaving a loose pellet of live sperm. Combine pellets using a
small amount of fertilization media and repellet at 1500 RPM for 3 minutes. Carefully remove
supernatant. Then gently mix the pellet. After determining the desired insemination dose,
inseminate the oocytes by adding sperm to the pellet, then culture in a dish and return to the CO
incubator for about 18-22 hours.
3. In Vitro Culture. Remove presumptive zygotes from the fertilization dish and transfer
into a sterile 1.5 mL eppendorf tube. Allow zygotes to form a loose pellet and remove excess
media to form a 1:1 ratio of pellet and solution. Rinse the eppendorf tube with TCM-199, place
contents into a dish and wash with BSA media. Then culture presumptive zygotes (discard
disfigured oocytes, as well as oocytes with yellow colored cytoplasm or vacuolated cytoplasm)
in a dual gas incubator (5% CO , 5% O ) at 38.5°C for about 48 hours.
4. Co-culture. Transfer cleaved zygotes to co-culture dishes comprising the cumulus cells
from the mature oocytes and FBS media topped with mineral oil, and incubate in a CO
incubator at 38.5°C until needed.
. Sperm Motility Evaluations by CASA. A comparison of viewing chambers and slides
can be done in a variety of IVOS instruments, which for example only can be a Hamilton-Thorne
IVOS (Hamilton-Thorne, Beverly, MA). Instrument settings: image capture; frames per second
= 60; number of frames = 30; cell detection; minimum contrast = 50; minimum cell size = 5;
defaults, cell size = 5; cell intensity = 50; progressive cells, path velocity = 50 um/s; straightness
≥ 70%; slow cells (um/s); average path velocity (VAP, <30 um/s), straight-line velocity (VSL,
<15 um/s). The CASA motility variables measured can be a percentage of total motile sperm
(motile), percentage of progressively motile sperm (progressive), VAO, VSL, curvilinear
velocity (VCL, um/s), average lateral head displacement (ALK, um) and the number of times the
sperm head crosses the mean path/s (BCF, Hz), straight-line sperm motility (STR, %), and linear
sperm motility (LIN, %). See for instance, Lenz, RW, et al., J Anim Sci (2011) 89:383-388,
incorporated by reference herein in its entirety.
A further aspect of the present disclosure entails the use of a sperm cell sample treated
with an OSR in AI. AI in the present disclosure includes a method whereby a fresh or frozen
thawed sperm cell sample is used to inseminate by way of passage of the semen or sperm sample
into the female reproductive tract, with or without an accessorizing tool such as an AI gun,
catheter or pipette.
Frozen semen samples may be contained in semen straws, which are thawed before the
AI procedure using standard methods. In certain embodiments described herein, the semen
straws contain about 0.25-0.5 ml of fluid and are often sufficient for a single insemination.
To increase the number of offspring that a female can produce, embryo transfer
techniques (such as MOET) have been developed and are well known to those skilled in the art.
Conventional embryo transfer techniques include injection of females with suitable hormones
that cause them to produce multiple eggs (oocytes) in a single estrous cycle. This process is
often referred to as superovulation. Each female is then artificially inseminated with a sperm cell
sample from a male that is either fresh or has been cryopreserved.
In another aspect described herein, zygotes and/or embryos from artificially inseminated
females can be recovered and then cultured and/or cryopreserved/vitrified.
Example 1
One set of semen from each bull was used as a control while to the remaining sets of
semen samples were added vitamin B12, as the antioxidant, at respective concentrations of
0.5mg/ml and 0.25mg/ml. For each sample, the same concentration of vitamin B12 was added
(i) during the staining process, and (ii) in the catch fluid of the collection vessel. Control samples
did not contain vitamin B12. Sperm samples were sorted in “High Purity” mode, and the
collected sex-sorted sperm were extended with a cryoextender, which in some cases again
contained the same concentration of vitamin B12 and the samples were frozen. Three hours after
thawing (which is a standard time frame to conduct quality control assessments on sorted frozen
thawed sperm samples) the thawed samples were put through CASA, a machine that provides
various data on sperm including motility and progressive motility information. The results are
shown below in Table 1 and the motility and progressive motility are graphically represented in
Figure 2.
In the tables below: VAP (average path velocity (µm/s)); VSL (straight-line velocity
(µm/s)); VCL (curvilinear velocity (µm/s)); ALH (average lateral head displacement (µm)); BCF
(the number of times the sperm head crosses the mean path/s in Hz); STR (percent straight-line
sperm motility); LIN (percent linear sperm motility); PIA (percent intact acrosomes); motile
(percent motile sperm); and progressive (percent progressively motile sperm).
The two step addition results represent treatments with vitamin B12 present at the same
indicated concentration in the catch fluid of the collecting vessel and in the cryoprotectant
extender prior to freezing the sample only (2 step-freeze; - + +); the three step addition results
indicate that the same concentration of vitamin B12 was added during the staining step, the
collecting step (in the catch fluid of the collecting vessel) and in the cryoprotectant extender
prior to freezing the sample (3 step). There is no correlation with regard to randomly assigned
names such as “Bull A.” Bull A from Example 5 is not the same bull as Bull A from Example 7.
TABLE 1: Motility (2 step and 3 step) (3 hrs Post-Thaw)
Total Motile Prog VAP VSL VCL ALH BCF STR LIN PIA
cells (%) Mot (%) (µm/s) (µm/s) (µm/s) (µm) (Hz) (%) (%) (%)
Bull 1
Control 562 59.5 33.5 54 47 95.5 4 21.5 87.5 51 73.5
0.5mg/ml, 2 step F 925 63.5 26 56 45 94 4 23 86.5 49 74
0.25mg/ml, 3 step 815 70.5 40.5 55 48 92 4 23.5 87.5 53 83
Bull 2
Control 529 54.5 41.5 61 53.5 107.5 4.5 23 87.5 51.5 64
0.5mg/ml, 2 step F 269 70.5 47 77 66 108 4 21.5 85.5 61 84
0.25mg/ml, 3 step 693 67 53.5 68 55 111.5 4.5 24 87 51 79.5
Bull 3
Control 599 47.5 18 49.5 42.5 84.5 4 20.5 86.5 51.5 52.5
0.5mg/ml, 2 step F 800 74.5 53.5 56 51 98 4 22.5 84.5 52.5 87
0.25mg/ml, 3 step 656 70 48.5 59 50 101 4 24 85.5 51 80
Bull 4
Control 602 65.5 33.5 53.5 45.5 89.5 4 23.5 86 52.5 72.5
0.5mg/ml, 2 step F 874 81.5 50 60 53 109 5 26 83.5 49 88
0.25mg/ml, 3 step 1059 81 25.5 43 51 88.5 5 23 82.5 47 86
Bull 5
Control 638 49.5 13 45.5 38.5 86.5 5 18 84 45.5 63.5
0.5mg/ml, 2 step F 842 51 33 50 47 101 5 20.5 84 47 79
0.25mg/ml, 3 step 787 70 40.5 61 48 106.5 5 21.5 84.5 47 80
Example 2
In another series of experiments, the CASA results regarding motility and progressive
motility after 4.5 hours after thawing sex-sorted samples against a control are shown below in
Table 2. The (2 step-freeze) results indicate that vitamin B12 at the same concentration was
present in the catch fluid of the collecting vessel and in the cryoprotectant extender prior to
freezing the sample; the (3 step) results indicate that the same concentration of vitamin B12 was
added during the staining step, the collecting step (in the catch fluid of the collecting vessel) and
in the cryoprotectant extender prior to freezing the sample.
With respect to “Bull A,” the two sets of results shown were obtained on two different
days using thawed samples from the same initially sorted batch of sperm. In both cases the
concentration of the vitamin B12 was 1mg/ml. For all other bulls in the table below unless
otherwise indicated, the concentration of vitamin B12 added was also 1mg/ml.
TABLE 2: Motility (4.5 hrs Post-Thaw)
Total cells Motile Progressive
Bull A
control 322 38 0
1 mg/ml – 2 step-F 250 41 8
1 mg/ml – 3 step 287 64 37
Bull A (day 2)
control 328 46 4
1 mg/ml – 2 step-F 433 71 31
1 mg/ml – 3 step 487 64 11
Bull B
control 298 33 1
1 mg/ml – 2 step-F 316 22 1
1 mg/ml – 3 step 237 59 19
Bull C
control 403 52 1
1 mg/ml – 2 step-F 432 76 43
1 mg/ml – 3 step 613 62 2
Bull D
control 644 37 3
1 mg/ml – 3 step 400 59 9
Bull E
control 653 41 1
1 mg/ml – 3 step 648 52 1
Bull F
control 638 39 7
0.5 mg/ml – 3 step 761 51 16
0.25 mg/ml – 3 step 730 60 23
Bull G
control 588 41 13
0.5 mg/ml – 3 step 162 65 57
0.25 mg/ml – 3 step 1003 56 32
Example 3
In an additional experiment, motility and progressive motility were checked 3.75 hours
after thawing a sex sorted semen sample treated with the antioxidant. The OSR was not added to
the control sample. The semen sample was derived from a single bull. 0.25 mg/ml concentration
of vitamin B12 was added to the test sample during the staining step, the collecting step (in the
catch fluid of the collecting vessel) and in the cryoprotectant extender prior to freezing the
sample. The results are shown in Table 3 below.
TABLE 3: Motility (3.75 hrs Post-Thaw)
Prog
Total Motile VAP VSL VCL ALH BCF STR LIN PIA
cells (%) (µm/s) (µm/s) (µm/s) (µm) (Hz) (%) (%) (%)
Bull 1
Control 452 7 0 37 28 71 3 16 74 40 41
0.25mg/ml, 3 step 536 39 5 40 34 76 5 17 85 45 70
Example 4
An experiment was designed to test the effect of OSR treated sperm cells on the
development of eggs fertilized with those sperm cells. In this experiment, bull semen from two
bulls was sex sorted with flow cytometry, with vitamin B12 present at equal concentrations in
the media used to stain the sperm cells, in the catch fluid of the collecting vessel and in the
cryoprotectant extender prior to freezing the sex sorted sample (3 step). For each bull, three
different concentrations of vitamin B12 were tested: 0.05mg/ml, 0.15mg/ml and 0.25mg/ml. The
control samples were not treated with vitamin B12.
Slaughterhouse oocytes were collected and washed 1X with about 3mL Hepes washing
media and with 1X with TCM-199 + 10% FBS. The oocytes were then cultured in maturation
media for 22 hrs in a CO incubator at 38.5°C. Cumulus cells were trimmed away from matured
oocytes, transferred to a fertilization dish, and returned to the CO incubator.
Frozen semen straws were thawed using standard procedures and centrifuged in 800µL of
Pure Sperm gradient at 2500 RPM for 10 minutes in order to remove egg, glycerol and other
debris. The supernatant was removed, leaving a loose pellet of live sperm. Pellets were combined
using a small amount of fertilization media and repelleted at 1500 RPM for 3 minutes. The
supernatant was then carefully removed and the pellet gently mixed. After determining the
desired insemination dose, the matured oocytes were then inseminated by adding sperm to the
pellet, cultured in a dish and returned to the CO incubator for about 18-22 hours.
Presumptive zygotes were removed from the fertilization dish and transferred into a
sterile 1.5 ml eppendorf tube. The zygotes were allowed to form a loose pellet and excess media
was removed to form a 1:1 ratio of pellet and solution. The eppendorf tube was vortexed for 90
seconds and then rinsed with TCM-199. The contents were placed into a dish and then washed
with BSA media. The presumptive zygotes were then cultured in a dual gas incubator (5% CO ,
% O ) at 38.5°C for about 48 hours. Cleaved zygotes were then transferred to co-culture dishes
comprising the cumulus cells from the mature oocytes and FBS media topped with mineral oil
and incubated in a CO incubator at 38.5°C.
Embryos were observed 7 days after IVF to check: Zyg (the number of zygotes put into
culture); 4-2C (the number of zygotes that underwent the 2 cell to 4 cell transition 48 hours after
IVF); 8C (the number of zygotes with 8 cells 48 hours after IVF); 8C% (the percentage of
zygotes having 8 cells 48 hours after IVF); % Clv (percent cleaved 48 hours after IVF); C1
(number of expanded and hatching and hatched blastocysts 7 days after IVF); C1- (number of
blastocysts 7 days after IVF); and C2 (number of early blastocysts and compact morulas 7 days
after IVF), Total Embs (total number of blastocysts = C1+ C1- + C2); Blast % (percent of
cultured zygotes resulting in blastocyst formation); Hatch # (the number of embryos shedding
the zona palucida in preparation for implantation observed at 8.5 days after IVF); and Hatch %
(percentage of embryos that shed the zona). The results are provided in Table 4 below.
TABLE 4: IVF - Embryo / Fertilization (3 step)
Total Blast Hatch H atch
Zyg 4-2C 8C 8C% % Clv C1 C1- C2
Embs % # %
Bull A
Control 96 36 8 8.3 45.8
1 0 5 6 6.3 2 33.3
Control 68 19 7 10.3 38.2 0 0 2 2 2.9 0 0.0
Control 91 31 19 20.9 54.9
2 3 10 15 16.5 5 33.3
255 86 34 (13.3) (47.1)
Total/Avg 3 3 17 23 (9.0) 7 (30.4)
0.05mg/ml 87 20 3 3.4 26.4 0 0 1 1 1.1 0 0.0
0.05mg/ml 95 26 9 9.5 36.8
1 0 1 2 2.1 1 50.0
0.05mg/ml 94 20 11 11.7 33.0
0 3 1 4 4.3 1 25.0
Total/Avg 276 66 23 (8.3) (32.2) 1 3 3 7 (2.5) 2 (28.6)
0.15mg/ml 89 25 4 4.5 32.6
0 1 4 5 5.6 0 0.0
0.15mg/ml 90 29 9 10.0 42.2
1 0 4 5 5.6 3 60.0
0.15mg/ml 91 24 6 6.6 33.0
2 1 4 7 7.7 3 42.9
Total/Avg 270 78 19 (7.0) (35.9)
3 2 12 17 (6.3) 6 (35.3)
0.25mg/ml 91 33 6 6.6 42.9
0 2 3 5 5.5 2 40.0
0.25mg/ml 93 38 20 21.5 62.4
4 2 10 16 17.2 10 62.5
0.25mg/ml 91 26 16 17.6 46.2
2 3 10 15 16.5 6 40.0
Total/Avg 275 97 42 (15.3) (50.5)
6 7 23 36 (13.1) 18 (50.0)
Bull B
Control 91 15 35 38.5 54.9
3 3 8 14 15.4 9 64.3
Control 90 25 29 32.2 60.0
4 5 9 18 20.0 10 55.6
Control 92 20 33 35.9 57.6
7 6 12 25 27.2 15 60.0
Total/Avg 273 60 97 (35.5) (57.5)
14 14 29 57 (20.9) 34 (59.6)
0.05mg/ml 90 18 40 44.4 64.4
2 4 13 19 21.1 9 47.4
0.05mg/ml 92 23 27 29.3 54.3
4 2 9 15 16.3 7 46.7
0.05mg/ml 93 22 27 29.0 52.7
3 13 21 22.6 8 38.1
Total/Avg 275 63 94 (34.2) (57.1)
11 9 35 55 (20.0) 24 (43.6)
0.15mg/ml 96 21 38 39.6 61.5
6 7 10 23 24.0 17 73.9
0.15mg/ml 93 32 14 15.1 49.5
2 3 6 11 11.8 6 54.5
0.15mg/ml 100 21 29 29.0 50.0
4 4 14 22 22.0 9 40.9
289 74 81 (28.0) (53.6)
Total/Avg 12 14 30 56 (19.4) 32 (57.1)
0.25mg/ml 92 24 34 37.0 63.0
3 11 19 20.7 14 73.7
0.25mg/ml 96 31 23 24.0 56.3
1 3 3 7 7.3 5 71.4
188 55 57 (30.3) (59.6)
Total/Avg 6 6 14 26 (13.8) 19 (73.1)
Example 5
A similar experiment as done in Example 4 was done to test the effect of OSR treated
sperm cells on the development of eggs fertilized using a higher concentration of the antioxidant,
comparing it to one of the earlier used concentrations. Semen samples from two bulls of different
breeds (one Holstein; one Jersey) were sex sorted using flow cytometry, again using vitamin B12
as the antioxidant, present at equal concentrations during staining, in the catch fluid of the
collecting vessel and in the cryoprotectant extender prior to freezing the sex sorted sample (3
step). For each bull, the two concentrations of vitamin B12 tested were: 0.5mg/ml and
0.25mg/ml. The control samples were not treated with vitamin B12. All experimental steps
were done the same as in Example 4. The results are shown in Table 5 below.
TABLE 5: IVF - Embryo Fertilization (3 step)
Total Blast Hatch Hatch
Zyg 4-2C 8C 8C% % Clv C1 C1- C2
Embs % # %
Bull A (Holstein)
Control
91 25 35 38.5 65.9 3 2 4 9 9.9 3 33.3
Control
93 40 19 20.4 63.4 1 2 3 3.2 0 0.0
Control
98 25 25 25.5 51.0 3 6 5 14 14.3 6 42.9
(60.1)
Total/Avg 282 90 79 28.0 6 9 11 26 (9.2) 9 (34.6)
0.25mg/ml
97 25 39 40.2 66.0 6 9 5 20 20.6 8 40.0
0.25mg/ml
97 34 30 30.9 66.0 5 6 5 16 16.5 4 25.0
0.25mg/ml
97 23 33 34.0 57.7 6 7 6 19 19.6 9 47.4
Total/Avg (63.2)
291 82 102 35.1 17 22 16 55 (18.9) 21 (38.2)
0.5mg/ml
94 25 34 36.2 62.8 0 3 3 6 6.4 1 16.7
0.5mg/ml
95 29 30 31.6 62.1 1 7 7 15 15.8 4 26.7
0.5mg/ml
93 18 35 37.6 57.0 5 7 8 20 21.5 11 55.0
Total/Avg (60.6)
282 72 99 35.1 6 17 18 41 (14.5) 16 (39.0)
Bull B (Jersey)
Control 97 39 39 40.2 80.4 5 5 3 13 13.4 7 53.8
Control
100 22 12 12.0 34.0 4 5 9 9.0 2 22.2
Control
100 22 29 29.0 51.0 2 5 1 8 8.0 3 37.5
Total/Avg 297 83 80 26.9 (55.1) 11 15 4 30 (10.1) 12 (40.0)
0.25mg/ml
94 25 45 47.9 74.5 5 9 4 18 19.1 12 66.7
0.25mg/ml
99 36 20 20.2 56.6 7 6 6 19 19.2 6 31.6
0.25mg/ml
99 17 46 46.5 63.6 5 7 8 20 20.2 9 45.0
Total/Avg
292 78 111 38.0 (64.8) 17 22 18 57 (19.5) 27 (47.4)
0.5mg/ml
100 40 34 34.0 74.0 4 6 1 11 11.0 5 45.5
0.5mg/ml
95 31 24 25.3 57.9 5 11 7 23 24.2 6 26.1
0.5mg/ml
99 15 46 46.5 61.6 8 5 5 18 18.2 9 50.0
Total/Avg
294 86 104 35.4 (64.5) 17 22 13 52 (17.7) 20 (38.5)
Example 6
Another experiment similar to Examples 4 and 5 was performed to test the reproducible
effect of OSR treated sperm cells regarding a single bull by monitoring the development of
embryos. Bull A (Holstein) was sampled three different times; Bull B was sampled five different
times; Bull C only one time; all semen samples were subjected to standard sex sorting
procedures using flow cytometry with vitamin B12 as the OSR at 0.25 mg/ml during the steps of
staining, collection in the catch fluid and prior to cryopreservation (3 step). The control samples
were not treated with vitamin B12. All experimental steps were done the same as in Example 4.
The results are provided in Table 6, below.
TABLE 6: IVF (3 step) - Reproducibility
Total Blast Freeze Hatch
Bull A
Zyg 4-2C 8C 8C% % Clv C1 C1- C2
(Holstein) Embs % % %
Trial 1
Control 507 85 119 23.5 40.2 34 19 31 84 16.6 10.5
0.25mg/ml
434 92 100 23.0 44.2 27 14 44 85 (19.6) 9.4
Trial 2
Control 993 238 287 28.9 52.9 54 26 86 166 16.7 8.1
0.25mg/ml
884 204 222 25.1 48.2 81 36 128 245 (27.7) 13.2
Trial 3
Control 907 209 215 23.7 46.7 70 27 90 187 20.6 10.7
0.25mg/ml
1053 230 285 27.1 48.9 83 39 129 251 (23.8) 11.6
Average - Control
(18.2) (9.6)
Average - 0.25 mg/ml
(24.5) (11.8)
Total Blast Freeze Hatch
Bull B
Zyg 4-2C 8C 8C% % Clv C1 C1- C2
(Holstein) Embs % % %
Trial 1
Control
507 85 119 23.5 40.2 34 19 31 84 16.6 10.5
0.25mg/ml 434 92 100 23.0 44.2 27 14 44 85 (19.6) 9.4
Trial 2
Control
993 238 287 28.9 52.9 54 26 86 166 16.7 8.1
0.25mg/ml
884 204 222 25.1 48.2 81 36 128 245 (27.7) 13.2
Trial 3
Control
907 209 215 23.7 46.7 70 27 90 187 20.6 10.7
0.25mg/ml
1053 230 285 27.1 48.9 83 39 129 251 (23.8) 11.6
Trial 4
Control
550 122 177 32.2 54.4 12 19 56 87 15.8 5.6
0.25mg/ml
595 124 183 30.8 51.6 12 8 52 72 (12.1) 3.4
Trial 5
Control
596 107 159 26.7 44.6 31 21 83 135 22.7 8.7
0.25mg/ml
636 137 185 29.1 50.6 27 24 79 130 (20.4) 8.0
Average - Control
(18.5) (8.8)
Average - 0.25 mg/ml (21.7) (9.7)
Total Blast Freeze Hatch
Zyg 4-2C 8C 8C% % Clv C1 C1- C2
Bull C
Embs % % %
Trial 1
Control 454 113 265 58.4 83.3 21 17 49 87 (19.2) (8.4)
0.25mg/ml 509 104 335 65.8 86.2 31 27 62 120 (23.6) (11.4)
Example 7
A larger scale experiment was done to further test the reproducibility similar to what was
done in Examples 6 and 7, but testing five bulls each three separate times. Semen samples from
five bulls were sampled and sex sorted using flow cytometry in accordance with the earlier
procedures and treated with 0.25 mg/ml vitamin B12 as the OSR (3 step). The control samples
were not treated with vitamin B12.
TABLE 7: Averaged Effect (Holstein and Jersey Mix)
Total Blast Hatch Hatch
Zyg 4-2C 8C 8C% % Clv C1 C1- C2
Embs % # %
Control-A1 993 238 287 28.9 52.9 54 26 86 166 16.7
Control-A2 507 85 119 23.5 40.2 34 19 31 84 16.6
Control-A3 907 209 215 23.7 46.7 70 27 90 187 20.6
Control-B1 96 36 8 8.3 45.8 1 0 5 6 6.3 2 33.3
Control-B2 68 19 7 10.3 38.2 0 0 2 2 2.9 0 0.0
Control-B3 91 31 19 20.9 54.9 2 3 10 15 16.5 5 33.3
Control-C1 91 15 35 38.5 54.9 3 3 8 14 15.4 9 64.3
Control-C2 90 25 29 32.2 60.0 4 5 9 18 20.0 10 55.6
Control-C3 92 20 33 35.9 57.6 7 6 12 25 27.2 15 60.0
Control-D1 97 39 39 40.2 80.4 5 5 3 13 13.4 7 53.8
Control-D2 100 22 12 12.0 34.0 4 5 9 9.0 2 22.2
Control-D3 100 22 29 29.0 51.0 2 5 1 8 8.0 3 37.5
Control-E1 91 25 35 38.5 65.9 3 2 4 9 9.9 3 33.3
Control-E2 93 40 19 20.4 63.4 1 2 3 3.2 0 0.0
Control-E3 98 25 25 25.5 51.0 3 6 5 14 14.3 6 42.9
.9 (50.1) 192 113 268 573 (16.3) (10.8)
Total/Avg 3514 851 911 62
0.25 –A1
884 204 222 25.1 48.2 81 36 128 245 27.7
0.25 –A2
434 92 100 23.0 44.2 27 14 44 85 19.6
0.25 –A3 1053 230 285 27.1 48.9 83 39 129 251 23.8
0.25 –B1
91 33 6 6.6 42.9 0 2 3 5 5.5 2 40.0
0.25 –B2
93 38 20 21.5 62.4 4 2 10 16 17.2 10 62.5
0.25 –B3
91 26 16 17.6 46.2 2 3 10 15 16.5 6 40.0
0.25 –C1
92 24 34 37.0 63.0 5 3 11 19 20.7 14 73.7
0.25 –C2
96 31 23 24.0 56.3 1 3 3 7 7.3 5 71.4
0.25 –C3
0.25 –D1
94 25 45 47.9 74.5 5 9 4 18 19.1 12 66.7
0.25 –D2
99 36 20 20.2 56.6 7 6 6 19 19.2 6 31.6
0.25 –D3 99 17 46 46.5 63.6 5 7 8 20 20.2 9 45.0
0.25 –E1
97 25 39 40.2 66.0 6 9 5 20 20.6 8 40.0
0.25 –E2
97 34 30 30.9 66.0 5 6 5 16 16.5 4 25.0
0.25 –E3
97 23 33 34.0 57.7 6 7 6 19 19.6 9 47.4
Total/Avg
3417 838 919 26.9 (51.4) 237 146 372 755 (22.1) 85 (11.3)
Example 8
In an additional experiment, post-thaw motility and progressive motility were checked
using CASA at 0, 3 and 5 hours after thawing sex sorted semen samples (sorted using flow
cytometry) treated with vitamin B12 as the antioxidant. The OSR was not added to the control
samples. The semen samples were derived from two Holstein bulls. 0.25 mg/ml concentration of
vitamin B12 was added to the test samples during the staining step, the collecting step (in the
catch fluid of the collecting vessel) and in the cryoprotectant extender prior to freezing the
sample (3 step). The results are shown in Table 8 below.
TABLE 8: Post-Thaw Motility (3 step)
Total Motile Prog VAP VSL VCL ALH BCF STR LIN PIA
Bull A
cells (%) Mot (%) (µm/s) (µm/s) (µm/s) (µm) (Hz) (%) (%) (%)
0 hr Post-Thaw:
Bull A - Control
1884 77 53 107 81 211 9 23 76 40
Bull A - Control
1275 74 51 99 75 198 9 24 77 41 90
Average
(76) (52) 103 78 205 9 24 77 41
Bull A – 0.25
1074 73 51 89 68 183 8 26 77 40
Bull A – 0.25
1519 69 50 101 78 195 8 27 78 43 90
Average
(71) (51) 95 73 189 8 27 78 42
3 hr Post-Thaw:
Bull A - Control
1064 48 3 38 29 76 6 14 77 40 56
Bull A - Control
683 53 7 44 36 80 5 17 84 46 63
Average
(50) (5) 41 32.5 78 5.5 15.5 80.5 43 59.5
Bull A – 0.25
870 64 22 48 39 84 8 14 77 41 86
Bull A – 0.25
978 46 7 41 31 83 8 14 77 38 76
Average (55) (15) 45 35 84 8 14 77 40 81
hr Post-Thaw:
Bull A - Control
903 40 8 14 11 25 3 7 14 9 52
Bull A - Control
517 15 1 12 10 18 2 10 17 18 60
Average
(27.5) (4.5) 13 10.5 21.5 2.5 8.5 15.5 13.5 56
Bull A – 0.25
708 61 26 17 17 23 2 6 13 12 79
Bull A – 0.25
747 34 7 20 16 28 3 8 14 13 72
Average
(47.5) (16.5) 18.5 16.5 25.5 2.5 7 13.5 12.5 75.5
Total Motile Prog VAP VSL VCL ALH BCF STR LIN PIA
Bull B
cells (%) Mot (%) (µm/s) (µm/s) (µm/s) (µm) (Hz) (%) (%) (%)
0 hr Post-Thaw:
Bull B - Control 1878 73 57 88 73 153 7 27 83 49
Bull B - Control
1706 72 54 83 69 142 6 28 84 51 90
Average
(73) (55.5) 85.5 71 148 7 28 84 50
Bull B – 0.25
1804 79 58 85 70 145 6 28 83 51
Bull B – 0.25
1150 79 54 81 67 143 6 29 84 51 90
Average
(79) (56) 83 69 144 6 29 84 51
3 hr Post-Thaw:
Bull B - Control
80 8 16 66 33 60
666 30 10 39 25
Bull B - Control 85 6 16 82 44 72
670 50 12 45 37
Average
(50) (11) 42 31 82.5 7 16 74 38.5 66
Bull B – 0.25
96 6 18 80 42 83
928 56 18 50 39
Bull B – 0.25
89 6 18 80 42 82
772 42 12 46 37
Average
(49) (15) 48 38 93 6 18 80 42 82.5
hr Post-Thaw:
Bull B - Control
52 0 26 40 31 46
539 0 0 40 16
Bull B - Control
44 0 71 75 39 61
609 0 0 35 26
Average
(0) (0) 37.5 21 48 0 48.5 57.5 35 53.5
Bull B – 0.25
85 7 14 70 34 83
902 43 4 41 28
Bull B – 0.25
70 4 14 57 32 73
721 21 0 38 21
Average
(32) (2) 39.5 24.5 77.5 5.5 14 63.5 33 78
Example 9
In an additional experiment, motility and progressive motility were checked at 0 hours
and 3 hours after thawing sex sorted semen samples (sorted using flow cytometry) treated with
the antioxidant, vitamin B12. The OSR was not added to the control sample. The semen samples
were derived from two different breeds of bull, one a Holstein the other Texas Longhorn. 0.25
mg/ml concentration of vitamin B12 was added to the test samples either (i) during the staining
step (1 step-stain); (ii) the staining step and the collecting step (in the catch fluid of the collecting
vessel) (2 step-stain); (iii) in the staining step, the collecting step and the freezing step (in the
cryoprotectant extender prior to freezing the sample) (3 step) – Table 9 (A) for 3 hr, and (B) for 0
hr; or (iv) only prior to the cryopreservation step (1 step-freeze) – Table 9 (C) for 3 hr.
TABLE 9 (A): 3 hr Post-Thaw Motility (3 step; 2 step-stain; 1 step-stain)
Bull 1 (TL) Total Motile Prog VAP VSL VCL ALH BCF STR LIN PIA
3 hr Post-Thaw cells (%) Mot (%) (µm/s) (µm/s) (µm/s) (µm) (Hz) (%) (%) (%)
Control
(12) (3) 42 35 77 3 19 83 46 23
3 step (+ + +)
42 25 55 47 101 5 23 84 48 73
2 step-stain (+ + -)
9 47 41 85 5 21 87 49 47
1 step-stain (+ - -)
37 23 56 47 84 5 16 85 57 52
Bull 2 (Jersey) Total Motile Prog VAP VSL VCL ALH BCF STR LIN PIA
cells (%) Mot (%) (µm/s) (µm/s) (µm/s) (µm) (Hz) (%) (%) (%)
3 hr Post-Thaw
Control (72) (63) 70 59 108 5 19 85 56 72
3 step (+ + +) 75 70 81 74 124 5 22 88 58 80
2 step-stain (+ + -) 57 35 60 50 105 5 19 84 48 78
1 step-stain (+ - -) 47 32 59 49 98 5 19 84 51 71
Total Motile Prog VAP VSL VCL ALH BCF STR LIN PIA
Average
cells (%) Mot (%) (µm/s) (µm/s) (µm/s) (µm) (Hz) (%) (%) (%)
Avg - Control
(42) (33) 56 47 92 4 19 84 51 48
3 step (+ + +)
58 47 68 60 112 5 23 86 53 77
2 step-stain (+ + -)
41 22 53 45 95 5 20 85 48 63
1 step-stain (+ - -)
42 28 57 48 91 5 18 85 54 61
TABLE 9 (B) – 0 hr Post-Thaw Motility (3 step; 2 step-stain; 1 step-stain)
Total Motile Prog VAP VSL VCL ALH BCF STR LIN PIA
Bull 1 (TL)
0 hr Post-Thaw cells (%) Mot (%) (µm/s) (µm/s) (µm/s) (µm) (Hz) (%) (%) (%)
Control (58.5) (49.5) 93.5 81.0 161.5 7.0 26.0 86.5 52.5
3 step (+ + +) 76 60 89.5 79.5 154.5 7.0 27.5 89.0 56.5
2 step-stain (+ + -) 57 48 96.0 84.0 168.0 7.0 25.5 87.5 52.0
1 step-stain (+ - -) 60.5 55 95.0 83.5 167.0 7.0 26.5 88.5 52.0
Bull 2 (Jersey) Total Motile Prog VAP VSL VCL ALH BCF STR LIN PIA
cells (%) Mot (%) (µm/s) (µm/s) (µm/s) (µm) (Hz) (%) (%) (%)
0 hr Post-Thaw
Control (79) (68) 105.0 89.0 179.0 7.0 26.0 86.0 53.0
3 step (+ + +) 70 57.7 94.5 82.0 165.5 6.5 30.0 86.5 52.0
2 step-stain (+ + -) 74 67 97.0 85.0 170.0 7.0 27.0 88.0 52.0
1 step-stain (+ - -) 80 71 104.0 88.0 189.0 8.0 26.0 85.0 49.0
TABLE 9 (C) – 3 hr Post-Thaw Motility (1 step-freeze)
Bull 3 Total Motile Prog Mot VAP VSL VCL ALH BCF STR LIN PIA
3 hr Post-Thaw Cells (%) (%) (µm/s) (µm/s) (µm/s) (µm) (Hz) (%) (%) (%)
Control 418 20 0 38 26 67 14 12 63
Control 238 29 0 35 23 53 0 14 59
Avg - Control 656 (24.5) (0) 36.5 24.5 60 7 13 61
1 step-freeze (- - +) 384 50 10 43 35 80 5 17 63
1 step-freeze (- - +) 385 59 17 48 40 86 5 19 83
1 step-freeze (- - +) 210 32 4 41 31 75 6 13 67
1 step-freeze (- - +) 301 45 11 45 33 81 6 13 85
Avg – 1 step-frz 1280 (46.5) (10.5) 44.25 34.75 80.5 5.5 15.5 74.5
Example 10
An additional experiment was conducted to assess the pregnancy rate of female bovines
inseminated with sorted sperm cell samples treated with an antioxidant. Semen samples from two
bulls were sex sorted using the protocol described above. 0.25 mg/ml concentration of vitamin
B12 was added to the test samples during the staining step, the collecting step (in the catch fluid
of the collecting vessel) and the freezing step (3 step).
Frozen semen straws containing sex sorted sperm cell samples were thawed using
standard procedures. An artificial insemination (AI) gun was warmed as needed to approach
body temperature of the recipient, and a straw was placed in the barrel of the insemination gun.
The sealed end of the straw was cut off and a plastic sheath was placed over the straw and gun
for hygienic purposes. The female was previously placed in a restraining shoot for insemination.
The gun was threaded through the vagina and cervix and semen distributed in the uterine body.
384 females were inseminated, each inseminated with a single sperm cell dose, and each dose
containing 2.1 million sperm cells in 0.25 ml. Pregnancy checks were made 33-40 days post
insemination with an ultrasound machine. The results are shown in Table 10 below.
TABLE 10: Pregnancies (3 step)
Inseminations Percent Pregnancy
Bull A Control 87 32.8
0.25mg/ml 100 35.6
Bull B Control 99 30.9
0.25mg/ml 98 27.0
Total/Average Control 186 (31.9)
Total/Average 0.25mg/ml 198 (31.3)
Example 11
Additional pregnancy field trials were performed using the sex-sorted semen treated with
vitamin B12 at 0.25 mg/ml added to the test samples during the staining step, the collecting step
and again in the freezing step (3-step), as done in Example 10 was evaluated another time
looking using semen from five different Holstein bulls. Each semen sample was split into control
and vitamin B12 (0.25 mg/ml) treatment groups, and later inseminated into primiparous recipient
heifers. Pregnancy checks were made 33-40 days post insemination using ultrasound. The
results are shows in Table 11 below.
TABLE 11: Pregnancies (3 step)
Inseminations
Antioxidant Percent Pregnancy
Bull A Control 27.9
0.25 mg/ml 28.4
Bull B Control 26.1
0.25 mg/ml 28.0
Bull C Control 32.8
0.25 mg/ml 35.6
Bull D Control 26.0
0.25 mg/ml 30.7
Bull E Control 50.0
0.25 mg/ml 57.0
Total/Average
Control (32.6)
Total/Average
0.25 mg/ml (35.9)
Example 12
The levels of DNA fragmentation were also screened using a DNA fragmentation
‘Halomax for animals’ kit (Halotech DNA, sl, Madrid, Spain) to determine if there were any
advantageous effects of using the antioxidants during the staining and processing of sex-sorted
sperm. Two different breeds of cattle, Jersey and Holstein, were examined using two different
concentrations of antioxidant, 0.25 mg/ml and 0.5 mg/ml of vitamin B12 with the 3 step protocol
adding the same concentration of OSR during cell staining, in the collection catch fluid and prior
to cryopreservation. One of the bulls was used to evaluate the effect of addition or omission of
OSR at one or more of the sperm sorting steps. Motility and the level of DNA fragmentation
were both recorded. The results are shown in Table 12 below.
TABLE 12: DNA Fragmentation (1 step-stain, 2 step, 3 step)
% Motility % DNA Fragmentation
0 hr 3 hr 0 hr 24 hr 48 hr
Bull A (Jersey)
Control 57 17 1 1 1.7
0.25mg/ml 72 51 0.3 0.3 0.7
0.5mg/ml 60 42 0.3 0.7 1.3
Bull B (Holstein)
Control 62 32 0.3 0.3 0.7
0.25mg/ml 67 32 0 0.3 0.3
0.5mg/ml 79 48 0.3 0.3 0.7
% Motility % DNA Fragmentation
Bull C (Jersey) 0 hr 3 hr 0 hr 24 hr 48 hr
Trial 1
Control 79 72 1 1 1
3 step (+ + +) 70 75 0 0.3 0.3
2 step-stain (+ + -) 74 57 0.3 1 1
1 step-stain (+ - -) 80 47 0.7 1 1.3
Trial 2
Control 59 12 0.3 1.7 1.7
3 step (+ + +) 76 42 0.3 0.3 0.7
2 step-stain (+ + -) 57 25 0.3 0.7 0.7
1 step-stain (+ - -) 61 37 0.7 1 1
Example 13
The effect of OSR on motility was evaluated as a function of the concentration of the sex-
sorted sperm in the frozen straw. Tests were performed using vitamin B12 as the OSR at three
different concentrations of the antioxidant: 0.15 mg/ml; 0.25 mg/ml and 0.35 mg/ml; all were
added to the test samples during the staining step, the collecting step and again in the freezing
step (3-step), as done in Example 8. Holstein sperm was evaluated at three sperm cell
concentrations based upon total number of sperm per straw: 1 million sperm/straw; 2.1 million
sperm/straw; and 5 million sperm/straw. Motility was recorded 3 hr post-thaw.
A Jersey sperm sample was also evaluated in the same manner using 0.15 mg/ml or 0.25
mg/ml vitamin B12 at each of the three stages (3 step), but only at the 2.1 million sperm/straw
concentration. The results are shown in Table 13.
TABLE 13: Frozen Sperm Cell Concentration (3 step)
(Holstein) Motile Prog VAP VSL VCL ALH BCF STR LIN PIA
1M/straw
Control 20 4 40 32 76 3 15 78 42 43
.15mg/ml 48 18 48 42 81 4 12 88 53 66
.25 mg/ml 48 29 55 47 92 4 22 87 53 58
.35 mg/ml 65 46 58 51 94 4 23 88 55 70
2.1M/straw
Control 28 2 39 33 73 6 16 85 46 41
.15mg/ml 49 10 44 38 79 5 18 86 48 72
.25 mg/ml 48 18 46 40 81 5 20 87 50 76
.35 mg/ml 46 30 58 51 99 5 23 88 53 60
5M/straw
Control 20 1 39 29 69 7 13 74 43 46
.25mg/ ml 24 2 41 28 69 7 14 70 42 68
.35mg/ ml 28 3 41 32 68 7 14 69 43 69
.5mg/ ml 14 3 43 30 71 6 15 70 43 50
(Jersey)
2.1M/straw
Control 25 2 37 28 55 2 11 76 52 53
.15mg/ml 25 4 42 35 75 6 15 84 47 63
.25mg/ml 48 20 51 43 87 5 20 85 50 78
Example 14
The effect of a different OSR on bovine sperm motility was evaluated after zero hour and
a three hour post-thaw period. The OSR, α-tocopheryl, a form of Vitamin E, was purchased as
‘polyoxyethanyl-α-tocopheryl sebacate’ in a 15% stock solution (Aldrich). Tests were performed
using α-tocopheryl as the OSR, at three different concentrations: 0.01 mg/ml; 0.1 mg/ml and 0.5
mg/ml; all were added to the test samples during the staining step, the collecting step and again
in the freezing step (3-step), as done in the prior Examples. Sex-sorted Holstein sperm was
evaluated using a standard sperm concentration of 2.1 million sperm/straw processed from three
separate bulls. Motility of the treated samples were compared to untreated controls and recorded
at 0 hr and 3 hr post-thaw.
TABLE 14: Motility with α-tocopheryl (vitamin E) (3 step)
Total
cells Motile Prog VAP VSL VCL ALH BCF STR LIN
Holstein
0 hr Post-Thaw
Bull A
Control 548 56 25 75 52 151 7 22 74 39
0.01 617 72 17 100 49 201 10 20 56 27
0.1 458 73 33 99 62 217 9 22 66 32
0.5 424 63 36 97 68 214 9 22 72 34
Bull B
Control 548 56 25 75 52 151 7 22 74 39
0.01 617 72 17 100 49 201 10 20 56 27
0.1 458 73 33 99 62 217 9 22 66 32
0.5 424 63 36 97 68 214 9 22 72 34
Bull C (1)
Control 280 50 30 66 51 140 7 20 78 39
0.01 530 59 39 89 68 188 10 20 76 38
0.1 518 63 35 86 61 196 10 20 72 33
0.5 269 30 17 75 53 179 8 22 72 31
Bull C (2)
Control 364 23 12 65 54 116 5 25 82 49
0.01 347 36 27 86 78 140 6 26 90 57
0.1 822 27 18 84 75 149 6 25 88 52
0.5 764 29 18 74 64 130 7 28 87 55
Holstein
3 hr Post-Thaw
Total
A-toc Motile Prog VAP VSL VCL ALH BCF STR LIN
cells
Bull A
Control 260 25 6 39 33 71 5 16 83 47
0.01 253 64 20 51 42 92 5 21 84 49
0.1 297 62 32 54 46 101 5 22 86 48
0.5 235 54 29 60 51 106 5 24 85 49
Bull B
Control 309 29 8 46 37 83 6 19 82 46
0.01 126 28 9 54 39 103 4 21 76 41
0.1 154 14 4 56 36 100 6 18 73 38
0.5 151 36 10 57 41 104 5 22 77 44
Bull C (1)
Control 200 14 2 40 33 77 5 18 83 44
0.01 222 19 3 41 38 60 4 29 93 70
0.1 155 15 5 49 41 94 7 21 84 45
0.5 82 26 13 50 44 89 5 18 87 50
Bull C (2)
Control 207 2 0 19 15 26 1 11 73 27
0.01 270 6 0 35 21 55 0 13 60 39
0.1 658 4 0 38 29 63 1 8 76 46
0.5 278 2 0 37 21 64 0 14 55 33
Example 15
The effect of a third OSR on bovine sperm motility was evaluated after zero hour, three
hour and six hour post-thaw periods. Alpha-ketoglutarate (AKG) was freshly made and used at
three different concentrations: 0.25 mg/ml; 0.35 mg/ml and 0.45 mg/ml; all were added to the
test samples during the staining step, the collecting step and again in the freezing step (3-step), as
done in the prior Examples. Sex-sorted Holstein and Jersey bovine sperm were evaluated using a
standard concentration of 2.1 M sperm/straw. Motility of the treated samples was compared to
untreated controls at 0 hr, 3 hr and 6 hr post-thaw.
TABLE 15: Alpha-keto Glutarate (AKG) (3 step)
Holstein – 0 hr Motile Prog VAP VSL VCL ALH BCF STR LIN
control 41 16 69 44 143 8 21 66 34
.25 mg/ ml 91 75 104 81 185 8 27 82 48
.35 mg/ ml 80 65 94 80 165 7 29 85 51
.45 mg/ ml 86 75 98 88 162 7 30 89 57
Holstein - 3hr Motile Prog VAP VSL VCL ALH BCF STR LIN PIA
control 4 0 36 24 53 0 10 67 48 44
77 60 99 79 176 7 26 81 45 89
.25 mg/ ml
63 48 85 70 145 6 25 83 50 80
.35 mg/ ml
.45 mg/ ml 60 56 94 80 145 5 24 85 56 80
Motile Prog VAP VSL VCL ALH BCF STR LIN PIA
Holstein - 3 hr
control 30 7 40 30 68 3 13 74 46 44
.25 mg/ ml 71 55 96 77 169 6 26 81 47 89
64 38 69 57 117 5 21 84 50
.35 mg/ ml 80
.45 mg/ ml 60 50 90 75 144 6 25 84 53 80
Holstein - 6 hr Motile Prog VAP VSL VCL ALH BCF STR LIN PIA
control 4 0 38 23 55 0 12 61 42 56
.25 mg/ ml 36 7 44 33 87 6 17 76 39 73
.35 mg/ ml 58 7 42 32 80 7 16 76 40 85
52 22 55 46 96 5 22 82 48 79
.45 mg/ ml
Holstein - 6 hr Motile Prog VAP VSL VCL ALH BCF STR LIN PIA
control 4 0 38 23 55 0 12 61 42 56
.25 mg/ ml 36 7 44 33 87 6 17 76 39 73
.35 mg/ ml 58 7 42 32 80 7 16 76 40 85
.45 mg/ ml 52 22 55 46 96 5 22 82 48 79
Jersey - 0 hr Motile Prog VAP VSL VCL ALH BCF STR LIN
control 72 60 82 72 141 6 25 87 53
.25 mg/ ml 67 51 83 68 152 7 24 83 48
.35 mg/ ml 57 43 79 63 146 6 25 82 47
.45 mg/ ml 81 66 81 70 133 6 27 87 56
Jersey - 3 hr Motile Prog VAP VSL VCL ALH BCF STR LIN PIA
control 13 1 36 24 65 2 14 66 38 42
.25 mg/ ml 33 16 65 49 117 5 24 79 46 62
.35 mg/ ml 26 10 59 46 110 6 25 80 45 54
.45 mg/ ml 59 25 67 50 66 6 25 78 45 71
Example 16
The effect of combining two antioxidants on bovine sperm motility was evaluated after
zero hour, three hour and six hour post-thaw periods. Vitamin B12 was used at 0.25 mg/ml and
fresh alpha-ketoglutarate (AKG) was used at 0.35 mg/ml. Either vitamin B12 or AKG or both
treatments were added at the designated concentrations during the staining step, the collecting
step and again in the freezing step (3-step), as done earlier. Sex-sorted sperm from three Jersey
bulls were evaluated using standard 2.1 M sperm/straw. Motility of the treated samples was
compared to untreated controls at 0 hr, 3 hr and 6 hr post-thaw.
TABLE 16: Combination AKG, Vitamin B12, and Combination (3 step)
Jersey 1 - 0hr Motile PROG VAP VSL VCL ALH BCF STR LIN
75 67 99 87 162 6 30 88 56
Control
B12 - 0.25 mg/ml 88 78 97 87 157 6 33 89 58
AKG - 0.35 mg/ml 87 75 93 81 148 6 31 88 57
COMBO 78 69 93 83 149 6 32 89 57
Jersey 1 - 3hr Motile PROG VAP VSL VCL ALH BCF STR LIN
Control 43 5 41 33 74 6 15 56 46
53 34 58 51 93 4 23 87 55
B12 - 0.25 mg/ml
AKG - 0.35 mg/ml 60 44 82 67 136 5 27 83 50
COMBO 51 36 79 63 129 5 25 80 50
Motile PROG VAP VSL VCL ALH BCF STR LIN
Jersey 1 - 6hr
Control 2 1 48 38 58 3 8 75 64
B12 - 0.25 mg/ml 37 2 38 28 61 4 15 73 48
36 18 50 42 90 4 22 82 46
AKG - 0.35 mg/ml
COMBO 35 6 45 34 81 5 17 76 43
Jersey 2 - 3hr Motile PROG VAP VSL VCL ALH BCF STR LIN
Control 18 1 35 22 57 5 13 61 38
B12 - 0.25 mg/ml 66 30 51 43 93 5 18 84 47
AKG - 0.35 mg/ml 64 50 78 62 117 5 19 82 56
50 38 72 57 124 5 24 80 48
COMBO
Jersey 2 - 6hr Motile PROG VAP VSL VCL ALH BCF STR LIN
1 0 16 16 35 0 0 50 23
Control
B12 - 0.25 mg/ml 24 1 36 24 51 1 17 65 47
AKG - 0.35 mg/ml 44 5 42 36 68 2 17 86 54
COMBO 46 18 61 46 111 5 21 77 44
Jersey 3 - 0hr
Control 80 60 100 80 186 8 26 81 46
B12 - 0.25 mg/ml 83 70 89 76 160 7 27 85 51
AKG - 0.35 mg/ml 86 73 95 82 170 7 27 85 50
COMBO 89 74 99 81 177 7 28 84 49
Jersey 3 - 3hr Motile PROG VAP VSL VCL ALH BCF STR LIN
Control 64 22 47 38 88 6 16 81 45
B12 - 0.25 mg/ml 73 52 64 52 104 10 20 81 51
80 44 69 53 118 6 19 79 47
AKG - 0.35 mg/ml
COMBO 77 30 56 44 107 7 19 79 42
Jersey 3 - 6hr Motile PROG VAP VSL VCL ALH BCF STR LIN
Control 16 0.5 38 24 54 1 17 64 47
B12 - 0.25 mg/ml 44 1 37 24 56 3 14 66 44
AKG - 0.35 mg/ml 79 11 46 33 84 6 15 74 41
72 12 49 34 98 8 16 71 35
COMBO
Example 17
In an additional experiment, motility and progressive motility of female and male sex-
sorted Deer sperm were checked at 0, 1 and 3 hours after thawing the sex sorted semen samples
that were treated with the antioxidant, vitamin B12 at two concentrations: 0.25 mg/ml and 0.35
mg/ml; all samples were treated during staining, catch and prior to cryopreservation (3 step).
The OSR was not added to the control sample. The semen samples were derived from two white
tailed bucks. Each sample was sorted for both male and female enriched populations of sperm.
TABLE 17: Deer (male and female) – Vitamin B12 (3 step)
0 HR FEMALE TOTAL MOTILE PROG VAP VSL VCL ALH BCF STR
CONTROL 1887 74 53 85 67 157 7 24 78
0.25 2803 82 53 83 62 157 7 24 74
0.35 2484 84 55 92 68 169 7 24 74
Buck A MALE
CONTROL 2939 81 55 94 70 178 7 24 76
0.25 3036 76 49 91 66 173 7 24 73
0.35 2448 86 54 98 71 181 8 24 73
FEMALE
CONTROL 2025 80 36 92 56 185 8 22 64
0.25 1531 82 40 91 56 179 7 22 65
0.35 1859 89 43 105 69 198 8 23 66
Buck B
MALE
CONTROL 2114 85 39 103 62 202 8 22 63
0.25 1169 81 35 109 63 219 8 23 61
0.35 1658 89 46 103 67 197 8 23 66
1 HR FEMALE TOTAL MOTILE PROG VAP VSL VCL ALH BCF STR
CONTROL 1286 64 29 86 57 170 8 21 68
Buck A
0.25 1380 78 41 97 64 185 8 21 67
0.35 1808 80 31 109 68 216 9 22 63
MALE MOTILE PROG VAP VSL VCL ALH BCF STR
CONTROL 1612 67 27 71 50 141 7 22 73
0.25 1817 57 23 64 45 125 7 22 70
0.35 3169 85 52 105 75 198 8 23 72
FEMALE MOTILE PROG VAP VSL VCL ALH BCF STR
CONTROL 1371 81 26 65 43 127 6 19 68
0.25 1541 83 28 84 51 158 8 19 64
0.35 2637 92 32 116 66 214 9 20 58
Buck B
MALE
CONTROL 1520 84 48 86 57 169 6 23 70
0.25 1086 84 46 104 66 203 8 22 67
0.35 1881 92 46 112 71 216 8 22 65
2 HR FEMALE TOTAL MOTILE PROG VAP VSL VCL ALH BCF STR
CONTROL 1188 58 16 58 42 114 7 18 74
0.25 1045 75 40 97 65 190 9 20 68
0.35 877 54 19 68 50 137 8 20 75
Buck A
MALE
CONTROL 1325 59 13 51 38 101 6 19 77
0.25 1523 56 24 66 46 130 6 22 70
0.35 1797 58 39 101 75 193 8 23 76
FEMALE MOTILE PROG VAP VSL VCL ALH BCF STR
CONTROL 1125 73 15 56 38 111 7 18 69
0.25 834 64 11 53 36 106 7 16 68
0.35 1378 85 26 100 57 190 8 19 60
Buck B
MALE
CONTROL 1603 77 37 66 46 126 6 19 73
0.25 866 78 47 95 67 177 7 21 71
0.35 1760 89 41 78 51 149 7 20 70
* * * * * * * * * *
As can be easily understood from the foregoing, the basic concepts of the present
invention may be embodied in a variety of ways. As such, the particular embodiments, elements,
terms, or expressions disclosed by the description, or shown in the figures accompanying this
application are not intended to be limiting, but rather are examples of the numerous and varied
embodiments generically encompassed by the invention or its equivalents with respect to any
particular element thereof. In addition, the specific description of a single embodiment or
element of the invention may not explicitly describe all embodiments or elements possible; many
alternatives are implicitly disclosed by the description and figures.
It should be understood that each element of an apparatus or each step of a method may
be described by an apparatus term or method term. Such terms can be substituted where desired
to make explicit the implicitly broad coverage to which this invention is entitled. As example, it
should be understood that all steps of a method may be disclosed as an action, a means for taking
that action, or as an element which causes that action. Similarly, each element of an apparatus
may be disclosed as the physical element or the action which that physical element facilitates.
As another example, the disclosure of a “sorter” should be understood to encompass disclosure
of the act of “sorting,” whether explicitly discussed or not, and conversely, effective disclosure
of the act of “sorting” should be understood to encompass disclosure of a “sorter.” Such
alternative terms for each element or step are to be understood to be explicitly included in the
description.
In addition, it should be understood that unless utilization of a specific term in this
application is inconsistent with common use and interpretation of that term, dictionary
definitions should be understood to be included in the description for each term as contained in
the Random House Webster’s Unabridged Dictionary, second edition, each definition hereby
incorporated by reference.
Moreover, for the purposes of the present invention, the term “a” or “an” before an item
also refers to one or more of that item; for example, “a container” refers to one or more of the
containers. As such, the terms “a” or “an”, “one or more” and “at least one” can be used
interchangeably herein. Further, as used herein the term “or” means "and/or" unless specifically
indicated otherwise.
The term "comprising" as used herein, is synonymous with “including,” “containing,” or
“characterized by,” and is inclusive or open-ended and does not exclude additional, unrecited
elements or method steps.
The background section of this patent application provides a statement of the field of
endeavor to which the invention pertains. This section may also incorporate or contain
paraphrasing of certain United States patents, patent applications, publications, or subject matter
of the claimed invention useful in relating information, problems, or concerns about the state of
technology to which the invention is drawn toward. It is not intended that any United States
patent, patent application, publication, statement or other information cited or incorporated
herein be interpreted, construed or deemed to be admitted as prior art with respect to the present
invention, and the terms used in those earlier documents which may be similarly used in this
disclosure, shall not alter the intended definition of those same terms as defined or intended
herein.
The claims set forth in this specification, if any, are hereby incorporated by reference as
part of the description of the current invention, and the applicant expressly reserves the right to
use all or a portion of such incorporated content as additional description to support any or all of
the claims or any element or component thereof. The applicant further expressly reserves the
right to move any portion or all of the incorporated content of such claims or any element or
component thereof from the description into the claims, or vice versa, as necessary to define the
invention for which protection is sought by this application or by any subsequent application or
continuation, division, or continuation-in-part application thereof, or to obtain any benefit for
reduction in fees in compliance with relevant patent laws, rules, or regulations of any country or
treaty, and such incorporate content shall survive the entire pendency of this application as well
as any subsequent continuation, division, continuation-in-part application filings or any reissue
or extension thereof.
The claims set forth in this specification are intended to describe the metes and bounds of
a limited number of the preferred embodiments of the invention and are not to be construed as
the broadest embodiment of the invention or a complete listing of embodiments of the invention
that may be claimed. The applicant does not waive any right to develop further claims based
upon the description set forth above as a part of any continuation, division, or continuation-in-
part, or similar application.
Claims (40)
1. A method of sorting a sperm cell sample comprising the steps of: a. staining a sperm cell sample with a first media; and b. sorting the sperm cell sample to form at least one subpopulation in a second media; wherein at least one of the first media or the second media comprises two or more Organic Stress Reducing Agents (“OSRs”), and wherein one of the two or more OSRs is selected from the group consisting of vitamin B12, a vitamin B12 vitamer and biologically active derivatives thereof, each at a concentration in the range of 0.01 mg/ml to 5 mg/ml.
2. The method of claim 1 further comprising the step of freezing the at least one subpopulation.
3. The method of claim 2, wherein the step of freezing the at least one subpopulation comprises freezing the at least one subpopulation in a third media.
4. The method of claim 3, wherein the third media comprises the two or more OSRs each at a concentration in the range of 0.01 mg/ml to 5 mg/ml.
5. The method as claimed in any one of claims 1-4, wherein another of the two or more OSRs is selected from the group consisting of vitamin E, a vitamin E vitamer, alpha ketoglutarate, a tocopherol, a tocotrienol, α-tocopheryl and biologically active derivatives thereof.
6. The method as claimed in claim 3, wherein the two or more OSRs are present in: the first media, the second media, or the third media.
7. The method as claimed in claim 3, wherein the two or more OSRs are present in: the first media and the second media, the first and third media, or the second media and the third media.
8. The method as claimed in claim 3, wherein the two or more OSRs are present in: the first media, the second media, and the third media.
9. The method as claimed in any one of claims 1-8, wherein the sperm cell sample is derived from a bovine, swine, ovine, equine, deer, elk, buffalo, canine, feline, chimpanzee, gorilla, whale, dolphin and other marine mammals.
10. The method as claimed in any one of claims 1-9, wherein the concentration of each of the two or more OSRs is in the range of 0.05 to 0.5 mg/ml.
11. The method as claimed in any one of claims 1-9, wherein the concentration of each of the two or more OSRs is selected from the group of: about 0.05 mg/ml; about 0.1 mg/ml; about 0.15 mg/ml; about 0.25 mg/ml; about 0.35 mg/ml; about 0.45 mg/ml; and about 0.5 mg/ml.
12. The method as claimed in any one of claims 1-9, wherein the concentration of each of the two or more OSRs is each about 0.25 mg/ml or about 0.35 mg/ml.
13. A sperm sample sorted by the method of any one of claims 1-12.
14. A method of fertilizing one or more non-human eggs comprising the steps of: a. adding a first media to a sperm cell sample; b. staining the sperm cell sample in the first media; c. sorting the sperm cell sample to form one or more subpopulations of sperm cells; d. collecting the subpopulation of sperm cells in a second media; e. mixing the subpopulation of sperm cells with one or more non-human eggs to fertilize one or more of the eggs; wherein the first media and/or the second media comprises two or more OSRs each at a concentration in the range of 0.01 mg/ml to 5 mg/ml, wherein one of the two or more OSRs is selected from the group consisting of vitamin B12, a vitamin B12 vitamer and biologically active derivatives thereof, and wherein the first media or the second media comprising the two or more OSRs may be prepared before addition to the sperm cell sample or by addition of a stock solution comprising the two or more OSRs to the sperm cell sample.
15. The method as claimed in claim 14, wherein another of the two or more OSRs is selected from the group consisting of vitamin E, a vitamin E vitamer, alpha ketoglutarate, a tocopherol, a tocotrienol, α-tocopheryl and biologically active derivatives thereof.
16. The method as claimed in claim 14 or claim 15, wherein the concentration of the two or more OSRs in the first media or the second media is each in the range of 0.05 to 0.5 mg/ml.
17. The method as claimed in claim 14 or claim 15, wherein the concentration of the two or more OSRs in the first media or the second media is selected from the group of: about 0.05 mg/ml; about 0.1 mg/ml; about 0.15 mg/ml; about 0.25 mg/ml; about 0.35 mg/ml; about 0.45 mg/ml; and about 0.5 mg/ml.
18. The method as claimed in claim 14 or claim 15, wherein the concentration of the two or more OSRs in the first media or the second media is each about 0.25 mg/ml or about 0.35 mg/ml.
19. The method as claimed in any one of claims 14-18, further comprising the following steps after step d.: freezing the subpopulation of sperm cells in a third media; and thawing the subpopulation of sperm cells.
20. The method as claimed in claim 19, wherein the third media comprises two or more OSRs each at a concentration in the range of 0.05 to 0.5 mg/ml, wherein one of the two or more OSRs is selected from the group consisting of vitamin B12, a vitamin B12 vitamer and biologically active derivatives thereof.
21. The method as claimed in claim 20, wherein the concentration of each of the two or more OSRs in the third media is selected from the group of: about 0.05 mg/ml; about 0.1 mg/ml; about 0.15 mg/ml; about 0.25 mg/ml; about 0.35 mg/ml; about 0.45 mg/ml; and about 0.5 mg/ml.
22. The method as claimed in claim 20, wherein the concentration of the two or more OSRs in the third media is each about 0.25 mg/ml or about 0.35 mg/ml.
23. The method as claimed in any one of claims 14-22, further comprising the following steps prior to step a.: freezing the sperm cell sample; and thawing the sperm cell sample.
24. The method as claimed in any one of claims 14-22, wherein the sperm cell sample is derived from a bovine, swine, ovine, equine, deer, elk, buffalo, canine, feline, chimpanzee, gorilla, whale, dolphin and other marine mammals.
25. The method as claimed in any one of claims 1-12 and 14-24, further comprising the step of ablating one or more unwanted sperm cell types.
26. A non-human, sorted embryo produced by the method of any one of claims 14-25.
27. The non-human, sorted embryo as claimed in claim 26 that is frozen or vitrified.
28. A gender sorted sperm cell composition comprising a gender sorted sperm cell sample and two or more OSRs each at a concentration in the range of 0.01 mg/ml to 5 mg/ml, wherein one of the two or more OSRs is selected from the group consisting of vitamin B12, a vitamin B12 vitamer and biologically active derivatives thereof.
29. The gender sorted sperm cell composition as claimed in claim 28, wherein another of the two or more OSRs is selected from the group consisting of vitamin E, a vitamin E vitamer, alpha ketoglutarate, a tocopherol, a tocotrienol, α-tocopheryl and biologically active derivatives thereof.
30. The gender sorted sperm cell composition as claimed in claim 28 or claim 29, wherein the concentration of each of the two or more OSRs is selected from the group of: about 0.05 mg/ml; about 0.1 mg/ml; about 0.15 mg/ml; about 0.25 mg/ml; about 0.35 mg/ml; about 0.45 mg/ml; and about 0.5 mg/ml.
31. The gender sorted sperm cell composition as claimed in claim 28 or claim 29, wherein the concentration of each of the two or more OSRs is about 0.15 mg/ml, about 0.25 mg/ml or about 0.35 mg/ml.
32. The gender sorted sperm cell composition as claimed in claim 28 or claim 29, wherein the concentration of each of the two or more OSRs is each about 0.25 mg/ml or about 0.35 mg/ml.
33. The gender sorted sperm cell composition as claimed in any one of claims 28-32, wherein the gender sorted sperm cell sample is unfrozen.
34. The gender sorted sperm cell composition as claimed in any one of claims 28-32, wherein the gender sorted sperm cell sample is frozen.
35. The gender sorted sperm cell composition of any one of claims 28-34, wherein the gender sorted sperm cell sample is derived from a bovine, swine, ovine, equine, deer, elk, buffalo, canine, feline, chimpanzee, gorilla, whale, dolphin and other marine mammals.
36. The gender sorted sperm cell composition of any one of claims 28-35, further comprising a cryoprotectant.
37. A method as claimed in claim 1 or 14, substantially as herein described with reference to any example thereof and with or without reference to the accompanying drawings.
38. A sperm sample as claimed in claim 3, substantially as herein described with reference to any example thereof and with or without reference to the accompanying drawings.
39. A non-human, sorted embryo as claimed in claim 26, substantially as herein described with reference to any example thereof and with or without reference to the accompanying drawings.
40. A gender sorted sperm cell as claimed in claim 28, substantially as herein described with reference to any example thereof and with or without reference to the accompanying drawings.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ712027A NZ712027B2 (en) | 2011-06-01 | 2012-06-01 | Compositions and methods for improving the quality of processed sperm |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161492151P | 2011-06-01 | 2011-06-01 | |
US61/492,151 | 2011-06-01 | ||
US201161569143P | 2011-12-09 | 2011-12-09 | |
US61/569,143 | 2011-12-09 | ||
US201161570691P | 2011-12-14 | 2011-12-14 | |
US61/570,691 | 2011-12-14 | ||
PCT/US2012/040553 WO2012167151A1 (en) | 2011-06-01 | 2012-06-01 | Compositions and methods for improving the quality of processed sperm |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ617706A NZ617706A (en) | 2015-10-30 |
NZ617706B2 true NZ617706B2 (en) | 2016-02-02 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10563170B2 (en) | Compositions and methods for improving the quality of processed sperm | |
US10226041B2 (en) | Compositions and methods for improving the quality of processed sperm | |
US7838210B2 (en) | Sperm suspensions for sorting into X or Y chromosome-bearing enriched populations | |
EP2269617A1 (en) | Process for enriching a population of sperm cells | |
US20230097054A1 (en) | Low sugar sperm media and compositions | |
AU2013202649B2 (en) | Compositions and methods for improving the quality of processed sperm | |
NZ617706B2 (en) | Compositions and methods for improving the quality of processed sperm | |
NZ712027B2 (en) | Compositions and methods for improving the quality of processed sperm | |
NZ731211B2 (en) | Compositions and methods for improving the quality of processed sperm | |
NZ725104B2 (en) | Compositions and methods for improving the quality of processed sperm | |
RU2775530C2 (en) | Method for sperm treatment, device and related medium compositions | |
BR132016001430E2 (en) | COMPOSITIONS AND METHODS TO IMPROVE THE QUALITY OF PROCESSED SPERM |